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Summary 
The scale-up of antiretroviral treatment (ART) of HIV/AIDS in resource-limited settings 
has been one of the largest public health operations of our time, and by the end of 2009 
more than 5 million people were receiving ART in low- and middle-income countries. 
Although several studies on ART efficacy in Africa have been published, the majority 
have been carried out in larger cities and usually with short follow-up time. To date, there 
is a paucity of research from rural settings, which often face additional challenges, such 
as shortages of health workers, transport difficulties and other logistical constraints. In 
the first part of the present study we reported long-term clinical and virological outcomes 
of ART in a rural hospital in Tanzania. 
 
In the second part of this study we addressed the lack of field-friendly tools for 
virological monitoring of patients on ART. Viral load and resistance testing, as 
recommended in high-income countries, are rarely available in resource-limited settings 
due to high costs and stringent requirements for storage and transport of plasma. 
Consequently, treatment failure in such settings usually passes unnoticed until patients 
develop severe immunodeficiency, at which stage widespread resistance is likely. Dried 
blood spots (DBS) are easy to collect and store, and can be a convenient alternative to 
plasma. Unlike plasma, DBS can be stored and shipped at ambient temperature, thus 
avoiding the need for cold chain and speedy transport to the laboratory. In our study, 
under field conditions in rural Tanzania, we assessed the performance of DBS in 
virological monitoring of patients on ART. 
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Haydom Lutheran Hospital has provided ART to HIV-infected patients since 2003. A 
combination of stavudine or zidovudine with lamivudine and either nevirapine or 
efavirenz is the standard first-line regimen, in accordance with WHO and Tanzanian 
guidelines. All patients who started ART from October 2003 through December 2007 
were included in a longitudinal cohort study. Standard techniques of survival analysis 
were used to estimate mortality and identify predictors of mortality. Virological efficacy 
and emergence of drug resistance was assessed in patients who had completed at least 6 
months of first-line ART. Viral load and resistance results obtained with a standard 
plasma-based method were compared with results obtained with the use of DBS.  
 
Paper I and II were epidemiological studies. We found a high mortality in this cohort, 
particularly the first months after initiating ART: estimated mortality was 19.2%, 29.0% 
and 41.7% after 3, 12 and 36 months, respectively. Anemia, malnutrition and 
thrombocytopenia were strong and independent predictors of mortality. A prognostic 
model based on hemoglobin level appeared to be a useful tool for initial risk assessment: 
estimated one year mortality was 3.7% in patients without anemia compared to 55.2% in 
those with severe anemia (<8 g/dL). Among patients who survived the first 6 months and 
remained in care, however, we found good long-term virological efficacy: viral 
suppression (<400 copies/mL) was observed in 187 of 212 (88.2%) patients after a 
median follow-up time of 22.3 months. In total, 18 patients harbored at least one 
clinically significant drug-resistance mutation, of whom 5 had thymidine analogue 
mutations associated with broad cross-resistance to nucleoside reverse transcriptase 
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inhibitors. Although the overall prevalence of drug resistance was relatively low, it 
increased with time and reached approximately 15% after 3-4 years on ART.  
 
Paper III and IV were laboratory studies. First, we compared the viral load levels in 98 
plasma-DBS pairs from patients on ART. In a linear regression model there was a strong 
correlation, with an R2 value of 0.75, between the two specimen types. Viral loads were 
on average slightly higher in plasma than DBS, but the mean difference was only 0.04 
log10 copies/mL. However, DBS had reduced sensitivity to detect HIV-1 RNA in samples 
with low-level viraemia (<3000 copies/mL). Subsequently, we compared genotypic 
resistance results from DBS with those of plasma in 36 ART-experienced individuals 
with treatment failure (viral load >1000 copies/mL). Overall, 34 of 36 (94%) DBS 
specimens were successfully genotyped, and there was high concordance between 
mutations found in plasma and DBS. Thirty of 34 (88%) patients had identical resistance 
profiles to antiretroviral drugs in plasma and DBS.  
 
In conclusion, we found a high early mortality in this cohort. Simple laboratory markers, 
especially hemoglobin level, appeared to be useful for initial risk assessment, and can be 
of particular use in settings without access to CD4 cell counts. Long-term virological 
efficacy rates were favorable, and drug resistance appeared to develop at the same rate as 
in high-income countries. Finally, we found that the use of DBS was a feasible and 
reliable option for viral load and resistance testing, and we believe that DBS could 
simplify virological monitoring in resource-limited settings. 
.   
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1. Background
1.1. History of HIV/AIDS 
The Acquired Immune Deficiency Syndrome (AIDS) was first described among 
homosexual men in USA in 1981 [1-5]. Two years later a retrovirus, later known as 
Human Immunodeficiency Virus (HIV), was identified as the causative agent of AIDS 
[6-8]. Since then HIV/AIDS has been reported worldwide, and more than 25 million 
individuals have died from AIDS over the past three decades [9]. 
 
HIV invades CD4 positive cells, and shortly after onset of the primary infection there is a 
significant decline in the CD4 cell count followed by a partial recovery [10]. Thereafter, 
the CD4 cell count decreases gradually over a period that usually lasts for several years, 
during which most patients are asymptomatic and many still unaware of their HIV 
infection. When the CD4 cell count has dropped to a critical level, usually below 200 
cells/μL, cellular immunodeficiency renders the patients susceptible to opportunistic 
infections and malignancies [11]. Figure 1 gives a schematic overview of disease 
progression in relation to CD4 cell count and viral load in untreated HIV infection. 
 
In the early years of the pandemic, HIV infection was a death sentence even in wealthy 
countries with good access to health care. Patients inevitably developed AIDS and died 
from opportunistic infections or malignancies on average approximately 10 years after 
seroconversion, ranging from <1 year to >20 years [12-15]. In 1987, the first 
antiretroviral drug, zidovudine, was introduced, raising hope of a cure. Shortly after, 
however, it was discovered that the HIV virus was capable of developing resistance to 
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zidovudine. Later, new antiretroviral drugs were released: didanosine in 1991, zalcitabine 
in 1992, stavudine in 1994 and lamivudine in 1995 [16], but most patients developed 
resistance successively to all new drugs given as monotherapy [17, 18]. 
 
Figure 1: Development of CD4 cell count, HIV RNA viral load and clinical symptoms 
after HIV infection (Source: Wikipedia) 
 
From 1996, the introduction of a new class of antiretroviral drugs, protease inhibitors, 
and the concept of highly active antiretroviral therapy (HAART), a combination therapy 
of at least 3 different antiretroviral drugs, radically changed the prognosis for people 
living with HIV [19, 20]. HIV-infected individuals who receive HAART are now able to 
live normal lives with a life expectancy that might approach that of non-HIV-infected 
individuals, particularly when treatment is initiated before severe immunodeficiency has 
developed [21-23]. Moreover, HAART effectively prevents HIV transmission from 
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pregnant women to their infants, reducing the overall transmission risk through 
pregnancy, delivery and breastfeeding from 21-43% to approximately 2% [24-26]. 
 
1.2. Epidemiology 
By the end of 2008, an estimated 33.4 million people were living with HIV/AIDS. Two 
million AIDS-related deaths occurred in 2008, and 2.7 million individuals were newly 
infected with HIV the same year. After a massive increase in the HIV prevalence and 
incidence in the 1980s and 1990s, the epidemic has stabilized over the past decade, and 
the number of new infections and AIDS-related deaths has decreased slightly (Figure 2) 
[9].  
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Figure 2: Global estimates of HIV prevalence, incidence and AIDS-related deaths 
(Source: UNAIDS/WHO [9]) 
 
 
There are large geographical differences in the distribution of HIV/AIDS (Figure 3). In 
North America and Europe the epidemic has been concentrated to certain risk groups, 
mainly men who have sex with men, injecting drug users and immigrants. In sub-Saharan 
Africa the epidemic is generalized, and the majority is infected through heterosexual 
exposure. Africa is the continent hardest hit by the pandemic, with an adult prevalence of 
14-26% in certain countries in Southern Africa [9].  
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Figure 3: Adults HIV prevalence in 2008, by country (Source: WHO) 
 
 
Our study was carried out in Tanzania (figure 4), a low-income country in East Africa, 
which was ranked 151 of 182 in the latest Human Development Index [27]. The total 
population is estimated to be 39.7 million, of whom approximately 75% reside in rural 
areas [28]. Tanzania experiences a generalized HIV epidemic with an estimated adult 
HIV prevalence of 5.7%, which translates into 2.3 million people currently living with 
HIV/AIDS [9]. Life expectancy at birth is 46.5 years, which is estimated to be ten years 
lower than it would have been without HIV/AIDS [29]. 
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Figure 4: Map of Tanzania 
 
Haydom 
 
1.3. Mortality
HIV-related mortality declined dramatically in industrialized countries after the 
introduction of HAART in 1996 [19, 20]. At the beginning of 1998, death rates among 
HIV-infected individuals in Europe had fallen to less than a fifth of the pre-HAART level 
[19]. Still, mortality exceeds that of the general population, particularly when treatment is 
initiated late, i.e. with a history of AIDS and low CD4 cell count [21, 23]. Although 
AIDS remains the most common cause of death, other conditions such as cardiovascular 
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disease, liver disease, pulmonary disease and non-AIDS malignancy, have become 
increasingly important and account for nearly half of the deaths in people living with HIV 
in North America [30].  
 
In resource-limited settings mortality data are scarcer. At the onset of the present study 
(in 2007), few results from routine antiretroviral treatment (ART) programs in Africa had 
been published. Some early studies showed overall good program performance, although 
with a high mortality, particularly the first months after initiating ART [31-37]. The 
higher early mortality in low-income compared to high-income countries seemed to be, at 
least partly, explained by later initiation of ART [38], and AIDS appeared to be the 
predominant cause of death [39].  
 
Most studies on ART in Africa have been carried out in larger cities [32-34, 36, 37], 
often with support from an international non-governmental organization [31, 33, 35], and 
usually with short follow-up time [33, 35-37]. To date, there is a paucity of research from 
rural settings, which often face additional challenges, such as shortages of health 
workers, transport difficulties and other logistical constraints. In Tanzania, as in many 
other African countries, the majority of the population reside in rural areas [28]. In the 
present study, therefore, we aimed to assess long-term outcomes of ART in a rural 
Tanzanian hospital. 
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1.4. Antiretroviral treatment 
Since the introduction of zidovudine in 1987, a number of new antiretroviral drugs have 
been released, and currently more than 25 individual drugs from six therapeutic classes 
are commercially available [16]. European guidelines recommend to start therapy with a 
backbone of two nucleoside reverse transcriptase inhibitors (NRTI), plus either a non-
nucleoside reverse transcriptase inhibitor (NNRTI) or a ritonavir-boosted protease 
inhibitor [40]. 
  
Until recently, the vast majority of HIV-infected individuals worldwide did not have 
access to ART due to poverty and lack of health care infrastructure. Over the past years, 
however, the World Health Organization (WHO), Joint United Nations Programme on 
HIV/AIDS (UNAIDS) and international non-governmental organizations have led a 
massive public health campaign aiming for universal access to ART. Simultaneously, 
generic competition has brought down prices of antiretroviral drugs from more than 
US$10,000 to less than US$70 per person per year, and the use of fixed-dose 
combination tablets has simplified treatment substantially [41].  
 
In 2002, the WHO issued guidelines for scaling up ART in resource-limited settings, 
followed by revisions in 2003, 2006 and 2010 advocating earlier initiation of treatment 
[42-45]. The WHO guidelines recommend a first-line regimen based on two NRTIs in 
combination with an NNRTI. The most widely used ART regimen today is a fixed-dose 
combination (1 tablet morning and evening) of stavudine, lamivudine and nevirapine 
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[46]; however, the latest WHO guidelines recommend to move away from this regimen 
because of the long-term toxicity of stavudine [45]. 
 
By the end of 2009, more than 5 million people were receiving ART in low- and middle-
income countries, which is a 13-fold expansion over the past 6 years (Figure 5) [46]. 
Inevitably, the long-term negative consequences of ART, including late drug toxicities, 
treatment failure and emergence of drug resistance, will become increasingly evident 
over the coming years [47-49]. Hence, as more and more people are receiving ART 
worldwide, huge challenges remain in terms of ensuring long-term efficacy of therapy.   
 
Figure 5: Number of people receiving ART in low- and middle-income countries 
(Source: WHO/UNAIDS/UNICEF [46]) 
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1.5. Resistance
Genomic heterogeneity is a key feature of HIV and new mutations occur frequently [50, 
51]. Under pressure of a specific antiretroviral drug, mutations conferring resistance to 
this particular drug will have an evolutionary advantage and the mutant virus might 
overgrow the wild-type virus. In such a setting, the HIV viral load may increase and 
immunodeficiency develop despite ART [17, 18].     
 
The key to long-term benefit of ART is sustained suppression of viral replication through 
provision of at least 3 different antiretroviral drugs given simultaneously [52-54]. In 
patients with suboptimal adherence or reduced serum drug concentrations for other 
reasons, selection of resistance can occur rapidly. The probability of drug resistance 
increases with duration of treatment, and in a study from UK nearly 30% harbored drug 
resistance after 6 years [55].  
 
The NNRTIs and lamivudine/emtricitabine are particularly vulnerable to emergence of 
resistance since single-base mutations may be sufficient to induce high-level resistance 
[56]. In resource-limited settings, 99% initiate an NNRTI-based first-line regimen, and 
therefore resistance is likely to become an increasing problem in the coming decade [46]. 
Indeed, some have argued that scaling up ART in Africa could create widespread drug 
resistance [57, 58]. However, at the onset of the present study, there was a scarcity of 
studies presenting long-term resistance results from Africa, particularly from rural areas.   
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1.6. Monitoring of treatment 
In high-income countries, monitoring of patients on ART with HIV-1 RNA viral load 
measurements and genotypic resistance testing is standard of care. Effective therapy 
should suppress the viral load to undetectable levels by 24 weeks and thereafter maintain 
full viral suppression. Patients with consistent viral load elevations during treatment 
should be tested for genotypic resistance, so that their ART regimen can be modified 
according to the resistance profile [40, 59].  
 
Early detection of treatment failure and prompt switch to a fully active second-line 
regimen is key to prevent accumulation of drug-resistance mutations, which could 
jeopardize future drug options [60-62]. Furthermore, effective suppression of viral 
replication is crucial to avoid the negative consequences of HIV-infection [63], and a 
delayed switch after treatment failure is associated with increased mortality [64, 65]. 
 
In resource-limited settings, however, viral load measurements and genotypic resistance 
testing are rarely available due to their high costs, complexity and stringent requirements 
for storage and transport of plasma. Hence, after a patient has initiated ART, it is often 
impossible to determine whether the treatment is effective or not. In settings without 
access to viral load monitoring, the WHO recommends to detect treatment failure by 
clinical (new or recurrent WHO stage 4 condition) or immunological (impaired CD4 cell 
response) criteria [44, 45]; however, recent studies have shown that these criteria have 
poor sensitivity and specificity in detecting true virological failure [66-70]. Using the 
WHO criteria, the majority of patients with treatment failure will not be detected until 
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they develop severe immunodeficiency or opportunistic disease, at which stage 
widespread resistance is likely [71, 72]. Furthermore, many patients will be misclassified 
as treatment failures despite adequate virological response, and risk premature switch to 
complex and expensive second-line therapy [73]. Thus, a vital question in the scale-up of 
ART remains unanswered: How can HIV viral load and drug resistance be monitored in 
settings with limited laboratory capacity?  
 
1.7. Dried blood spots 
Dried blood spots (DBS) can be a practical tool to overcome the challenges associated 
with storage and transport of blood specimens in settings with limited infrastructure. 
Plasma samples require a trained phlebotomist, electricity for centrifugation, a freezer for 
storage, and ultimately a functioning cold chain and speedy transport to the laboratory. 
DBS, on the other hand, are prepared by spotting whole-blood onto a filter paper, either 
from venous blood or directly from a finger prick, making this method particularly 
suitable in rural settings where laboratory personnel are scarce (Figure 6). Furthermore, 
DBS packed in zip-lock plastic bags with desiccant can be stored and shipped at ambient 
temperature, thus avoiding the requirement for a freezer and carriage on dry ice [74]. 
DBS specimens can be sent by truck or bus to the reference laboratory, or simply by the 
postal system where available. Biohazard risks associated with shipment are minimized 
since DBS cannot break and HIV on the filter paper matrix looses infectivity on drying 
[75].   
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Figure 6: Dried blood spots (DBS) on a Whatman 903 filter paper. 
 
 
DBS have been used for more than 40 years to screen for metabolic disorders in neonates 
[76]. Recently, several African countries, including South Africa with the world’s largest 
HIV-positive population, started to use DBS to screen for HIV in infants born of HIV-
infected mothers. Detection of HIV-1 DNA in DBS is a highly sensitive and specific test 
of HIV-infection in infants [77]. Hence, the use of DBS is already familiar to health care 
providers and laboratory technicians in several low-income countries. 
 
Prior to the onset of our study, a few studies had shown that DBS could be used to 
reliably measure HIV-1 RNA viral load [74, 78-81] and genotypic drug resistance [82]. 
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However, these studies were carried out under standardized conditions in modern 
laboratories, and did not necessarily reflect real-life application in resource-limited 
settings. Hence, there was a need to validate the use of DBS for virological monitoring 
under field conditions in rural Africa, the setting where it would be of most use. 
 
1.8. About Haydom Lutheran Hospital 
Haydom Lutheran Hospital is a 400-bed hospital in Manyara region in northern Tanzania. 
It was founded by the Norwegian Lutheran Mission in 1953 and handed over to the 
Evangelical Lutheran Church of Tanzania 10 years later. The hospital is the main health 
care provider to a rural population of about 260,000 people, and available services 
include a fairly well equipped laboratory with microscopy, bacteriology and 
biochemistry, a modern radiology department with ultrasonography and computer 
tomography, as well as standard surgical and obstetrical services.  
 
Adult HIV prevalence in the area is estimated to be 1.8% [83]. In 2002, the hospital 
launched a comprehensive HIV prevention and intervention program, funded by the 
Royal Norwegian Embassy and the US President’s Emergency Plan for AIDS Relief 
(PEPFAR), with emphasis on voluntary testing and counselling through outreach services 
and antenatal clinics. An HIV Care and Treatment Centre was established adjacent to the 
hospital, and from October 2003 ART has been provided free of charge to eligible HIV-
infected patients. Clinical officers, under supervision of a physician, have been 
responsible for medical follow-up of patients. On-site training was provided by HIV 
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specialists from collaborating institutions in Norway. A community home-based care 
network was established to follow-up adherence and trace missing patients.  
 
Haydom Lutheran Hospital has always enjoyed good connections to Norway through 
financial support and visiting specialists. Furthermore, Haydom Lutheran Hospital has 
been involved in clinical research for several years through its collaboration with various 
Norwegian institutions, including University of Bergen, University of Oslo and Sørlandet 
Hospital. In 2007, the National Institute for Medical Research in Tanzania set up a 
research station at Haydom to coordinate the different research activities. 
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2. Aim and objectives 
2.1. Main aim:
Assess the efficacy of modern antiretroviral treatment of HIV/AIDS at a rural hospital in 
Tanzania, and explore simplified laboratory methods for monitoring of treatment. 
 
2.2. Specific objectives: 
 Assess mortality and other program losses among patients who initiate ART (Paper 
I). 
 Study virological efficacy and emergence of drug resistance in patients who receive 
ART (Paper II). 
 Identify predictors of mortality and drug resistance in patients who initiate ART 
(Paper I and II) 
 Validate the use of dried blood spots under field conditions for monitoring of HIV-1 
RNA viral load (Paper III). 
 Validate the use of dried blood spots under field conditions for genotypic resistance 
testing (Paper IV). 
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3. Material and methods 
3.1. Patients, treatment and follow-up 
Most of the patients enrolled in the HIV program in Haydom were diagnosed either 
through HIV testing and counselling in the villages or they were hospitalized patients 
tested on clinical suspicion. Therefore, many of the patients had advanced 
immunodeficiency at the time of enrolment into HIV care. In our study we decided to 
include all patients regardless of presumed prognosis. This strategy was adopted to get a 
representative picture of a routine ART program in rural Tanzania. 
 
ART was initiated in accordance with guidelines from the WHO and the National AIDS 
Control Program [42-44, 84]: WHO stage 4 irrespective of CD4 cell count, WHO stage 3 
with CD4 350 cells/μL, or CD4 200 cells/μL with any WHO stage. However, reliable 
CD4 cell counts were not available until September 2006; thus, most patients started 
ART based on clinical criteria only (WHO stage 3 or 4). In addition, triple-drug 
combination ART, and not single-dose nevirapine which has been used widely in other 
programs, was offered to HIV-infected pregnant and lactating women, from pregnancy 
week 20 till cessation of breast-feeding, irrespective of WHO stage and CD4 cell count, 
to prevent mother-to-child transmission.  
 
First-line treatment comprised stavudine or zidovudine, combined with lamivudine, and 
either nevirapine or efavirenz. Regimen choice was subject to availability, with use of a 
generic fixed-dose combination of stavudine, lamivudine and nevirapine whenever 
possible. Second-line treatment was available from December 2006 and comprised 
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lopinavir/ritonavir, didanosine and abacavir. Criteria for switching to second-line ART 
was virological failure as recommended in the 2006 revision of the WHO guidelines (i.e. 
viral load >10,000 copies/mL) [44]; however, viral load was not measured routinely, and 
only selected patients with high clinical suspicion of failure were tested. Patients with 
CD4 200 cells/μL or WHO stage 3 or 4 disease were given co-trimoxazole prophylaxis 
960 mg thrice weekly or 480 mg daily. After the initial 2 weeks of daily drug 
administration, antiretroviral drugs were dispensed on a monthly basis. Patients were 
seen by a clinical officer every 3 months, and CD4 cell counts were performed every 3-6 
months. 
 
3.2. Data collection 
Data for the study was collected from the patient files at the HIV Care and Treatment 
Centre. A standardized form was used for the baseline evaluation, which included socio-
demographic information, medical history, physical examination and laboratory 
investigations (Appendix). Clinical staging was performed using the most updated 
revision of the WHO clinical staging system [42-44].  
 
Deaths were registered from hospital records or reported through home visitors. The 
home visitors recorded date of death and likely death cause (or symptoms preceding 
death) by interviewing relatives of the deceased. There is no central death register in 
Tanzania, making the assessment difficult in patients who moved out of the hospital’s 
catchment area, but the clinic staff attempted to trace all patients who failed to attend the 
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clinic. Patients who missed appointments for more than 3 months, and could not be traced 
by the home visitor, were regarded lost to follow-up. 
 
3.3. Laboratory methods 
3.3.1. Routine tests performed at Haydom Lutheran Hospital 
Standard laboratory investigations at baseline included: Full blood cell count, CD4 cell 
count, erythrocyte sedimentation rate, liver function tests, creatinine, blood sugar, 
hepatitis B surface antigen and syphilis serology. 
 
HIV infection was established using two different rapid antibody tests. Standard 
hematology was measured using Sysmex KX-21 Hematology Analyzer (Sysmex Corp., 
Kobe, Japan). CD4 cell counts were initially measured by manual techniques (Dynabeads 
CD4; Dynal Biotech ASA, Oslo, Norway); however, results were observed to be 
unreliable, and from September 2006 an automated flow cytometer (FACSCount; Becton 
Dickinson, San Jose, CA, USA) was employed. For the purpose of this study only CD4 
cell counts from the FACSCount were considered. 
 
Body mass index (BMI, weight in kilograms divided by height in meters squared) was 
used to assess nutritional status. Body weight was measured at each clinic visit using the 
same manual scale, and height was measured at baseline using a stadiometer mounted on 
the scale. 
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3.3.2. HIV-1 RNA viral load 
HIV-1 RNA viral load was not a routine test in the program, but was performed as part of 
the current study in patients who had completed at least 6 months of first-line ART. 
Blood was collected on plasma preparation tubes (PPT; Becton Dickinson, Franklin 
Lakes, NJ, USA) by venous puncture and centrifuged within 3 hours. Plasma was 
immediately transferred to sterile plastic tubes and stored at -20°C. Manufacturer’s 
instructions were followed with regard to sample collection, storage and transport. Viral 
load was measured at Muhimbili National Hospital, Dar es Salaam, Tanzania, using the 
Cobas TaqMan 48 Analyzer (Roche Diagnostics, Branchburg, NJ, USA) with a lower 
detection limit at 40 copies/mL. However, due to equipment breakdown, a subset of 
samples were analysed with the Cobas Amplicor HIV-1 Monitor v1.5 (Roche 
Diagnostics) with a detection limit at 400 copies/mL.  
 
As a quality control, 7 random duplicate samples were sent without prior freezing to Oslo 
University Hospital and tested within 48 hours of sample collection, using the same viral 
load assay (Cobas TaqMan 48 Analyzer; Roche Diagnostics). Results from Oslo 
University Hospital showed good agreement with samples tested at Muhimbili National 
Hospital after 5 weeks storage in Haydom at -20°C (Table 1); the mean difference was 
only 0.06 log10 copies/mL (standard deviation [SD] 0.22). 
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Table 1: Comparison of viral load results (log10  copies/mL) from Oslo University 
Hospital (OUS) and Muhimbili National Hospital (MNH) in 7 duplicate plasma 
specimens 
 1 2 3 4 5 6 7 Mean
MNH 5.20 5.81 3.42 5.32 3.31 5.96 6.43 4.95
OUS 5.23 5.69 3.71 5.17 3.73 6.00 6.34 5.01
Difference -0.03 0.12 -0.29 0.15 -0.42 -0.04 0.09 -0.06
 
3.3.3. Genotypic resistance testing 
Resistance testing was not available in Tanzania at the time of our study. For the purpose 
of this study we were granted permission to ship samples to Oslo University Hospital for 
genotyping. Plasma was genotyped using the routine method at Oslo University Hospital, 
which comprises the ViroSeq HIV-1 Genotyping System v2.0 (Abbott Molecular, Des 
Plains, IL, USA) with inclusion of an in-house reverse transcriptase (RT)-nested 
polymerase chain reaction (PCR) step, as described in detail in paper II and IV.  
 
3.3.4. Dried blood spots 
DBS were prepared in parallel with plasma from the same blood samples. Whole-blood 
from a PPT tube was spotted onto two Whatman 903 filter paper cards (Whatman plc, 
Maidstone, UK) to completely fill the circles. The cards were then left to air-dry 
overnight, and stored in zip-lock plastic dispensing bags (purchased locally) with a silica 
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desiccant (Elcon-Broker AS, Holmestrand, Norway). The two DBS cards were stored and 
processed differently: 
1) Stored locally at -20°C, but exposed to ambient temperature for 20 days during 
transport: these samples were used for the viral load study (Paper III). 
2) Stored and shipped at ambient temperature: these samples were used for the 
resistance study (Paper IV). 
In order to extract and isolate nucleic acids from the filter papers, we used the NucliSens 
silica-based Boom extraction method (BioMérieux, Inc., Durham, NC, USA) with some 
modifications for DBS processing [85, 86]. The procedure is described in detail in paper 
III and IV.  
 
 
Viral load quantification from DBS was performed using the NucliSens EasyQ HIV-1 
v1.2 (BioMérieux), which comprises nucleic acid sequence-based amplification 
(NASBA) and real-time detection using molecular beacons targeting the gag gene. The 
NASBA method is an isothermal amplification (41ºC), which specifically amplifies 
single-stranded RNA, by the use of T7 RNA polymerase. It has a linear dynamic range 
from 50 to 3,000,000 IU/mL when 1 mL of plasma is used [87].  
 
Genotyping from DBS, after manual extraction and isolation of nucleic acids, was carried 
out using the same method as for plasma, as described above.  
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3.4. Study design 
HIV-infected individuals who started ART were included in a prospective cohort study. 
Specific inclusion and exclusion criteria are listed in each paper. 
 
Paper I and II were epidemiological studies:  
Paper I assessed mortality in an open cohort of adults (15 years) who 
successively started ART. A longitudinal cohort study is well suited to describe 
mortality and investigate possible associations between various factors and death 
[88]. Women who started ART exclusively to prevent mother-to-child 
transmission, and not for their own health, were excluded from this paper, since 
they were essentially a different population than those who started ART due to 
immunodeficiency. 
Paper II assessed virological efficacy of ART in a cross-sectional survey of 
adults (15 years) who had completed at least 6 months of first-line ART. We 
aimed to include all patients on ART at the time of the survey, but excluded 
those who for various reasons had stopped ART. A cross-sectional survey is 
suitable to determine the prevalence of various conditions, in this case virological 
failure and drug resistance [89].  
 
Paper III and IV were experimental laboratory studies:  
Paper III compared HIV-1 RNA viral loads in DBS with results from a 
plasma-based method, using samples obtained from patients on ART. 
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Paper IV compared HIV-1 genotypes derived from DBS with those of plasma, 
using samples from patients with treatment failure (viral load >1000 copies/mL).    
 
3.5. Statistical analysis 
We used standard techniques of survival analysis to estimate mortality and identify 
predictors of mortality (Paper I). Kaplan-Meier models were used to estimate mortality 
after ART initiation, and log rank tests to compare survival curves. Cox proportional 
hazards models were used to identify independent predictors of mortality and calculate 
hazard ratios [88]. 
 
Logistic regression was used to study associations between baseline characteristics and 
emergence of drug resistance (Paper II). Since this part of our study was based on a 
cross-sectional survey, we could not ascertain when resistance mutations had emerged, 
and therefore techniques of survival analysis would not be appropriate [88]. 
 
We used linear regression analysis on log10-transformed data to compare viral load 
results in DBS and plasma, and employed the analysis described by Bland and Altm
describe agreement between the two methods (Paper III) [90]. Thereafter, to assess the 
ability of DBS to identify patients with major virological failure (5000 copies/mL), we 
used Receiver Operating Characteristics (ROC) curves to identify the optimal threshold 
in DBS and the corresponding sensitivity and specificity. The area under the ROC curve 
ranges from 0.5 in a completely random test to 1.0 when there is perfect agreement, and 
this method provides a graphical representation of the tradeoff between sensitivity and 
an to 
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specificity. ROC curves are commonly used for the purpose of assessing a new diagnostic 
method against the standard method [91]. 
 
Finally, we used simple descriptive statistics to compare resistance mutations in DBS and 
plasma with regard to amplification success, detection of mutations, and nucleotide 
similarity (Paper IV). Logistic regression was used to study factors associated with 
amplification failure in DBS. 
 
Data were analyzed using SPSS (version 14.0-16.0) for Windows (SPSS Inc., Chicago, 
IL, USA), except 95% confidence intervals for proportions which were calculated with 
NCSS version 2007 (NCSS, Kaysville, UT, USA). All tests were two-sided and level of 
significance was set at P <0.05. 
 
3.6. Ethical considerations 
Ethical approval, including permission to take blood samples to Norway, was obtained 
from the Medical Research Coordinating Committee of the National Institute for Medical 
Research (NIMR) in Tanzania and Regional Committee for Medical Research Ethics 
(REK-Øst) in Norway. Permission to carry out the research was granted by the hospital 
management at Haydom Lutheran Hospital and Personvernombudet at Oslo University 
Hospital. Patients gave written consent to participate in the study. 
 
We performed viral load and resistance testing on a number of patients, and every effort 
was taken to make sure the test result was communicated back to the clinician in charge 
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and proper action taken. This would sometimes involve purchasing second-line 
antiretroviral drugs or other medicines not available locally for selected patients. We 
consider this an obligation of medical research in low-income countries.    
 
It felt like a heavy responsibility to perform research involving patients who were often 
critically ill. During the data collection period in Haydom, I felt obliged to participate in 
the clinical work at the hospital in order to contribute with my medical skills in a rural 
hospital with a desperate need for healthcare professionals. The clinical work at the 
hospital was truly one of the most rewarding experiences as a PhD fellow. 
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4. Synopsis of results 
4.1. Paper I: Predictors of mortality in HIV-infected patients 
starting antiretroviral therapy in a rural hospital in Tanzania 
This paper aimed to assess mortality and to identify predictors of mortality among 
individuals who started ART. Of 320 patients included, 223 (69.7%) were women and 
median age was 35 years (interquartile range [IQR] 30-43). At ART initiation, 210 
patients (65.6%) had clinical AIDS (WHO stage 4). After a median follow-up period of 
10.9 months (IQR 2.9-19.5) we found that 95 of 320 (29.7%) patients had died, of whom 
59 died within the first 3 months after starting ART. Kaplan-Meier estimated survival 
was 0.808, 0.710, 0.648 and 0.593 after 3, 12, 24 and 36 months, respectively. In a Cox 
proportional hazards model the following baseline variables were independent predictors 
of mortality:  
severe anemia (hemoglobin <8 g/dL; adjusted hazard ratio [AHR] 9.20; 95% 
confidence interval [CI] 2.05-41.3) 
moderate anemia (hemoglobin 8-9.9 g/dL; AHR 7.50; 95% CI 1.77-31.9) 
thrombocytopenia (platelet count <150 x 109/L; AHR 2.30; 95% CI 1.33-3.99) 
severe malnutrition (BMI <16 kg/m2; AHR 2.12; 95% CI 1.06-4.24). 
 
A simple prognostic model based on hemoglobin level appeared to be a useful tool for 
initial risk assessment in this setting: Estimated one year mortality was 3.7% in patients 
without anemia, 20.0% in mild anemia, 37.6% in moderate anemia and 55.2% in severe 
anemia (P <0.001). A similar trend was observed with decreasing BMI: Estimated one 
 39
year mortality was 13.7% in patients with normal nutritional status, 21.0% in mild to 
moderate malnutrition, and 46.8% in severe malnutrition (P <0.001).  
 
In conclusion, this study found a high early mortality among patients who started ART, 
and anemia, thrombocytopenia and low BMI were strong predictors of mortality.  
 
4.2. Paper II: Virological efficacy and emergence of drug 
resistance in adults on antiretroviral treatment in rural 
Tanzania 
In this paper we assessed virological efficacy and emergence of genotypic resistance 
among 212 patients who had received ART for at least 6 months (median follow-up time 
22.3 months; IQR 14.0-29.9). Viral suppression (viral load <400 copies/mL) was 
observed in 187 patients (88.2%). The proportion of patients (95% CI) with suppressed 
viraemia after 1, 2, 3 and 4 years was 94.8% (87.2-98.6), 88.0% (79.0-94.1), 75.0% 
(57.8-87.9) and 87.5% (61.7-98.4), respectively. 
 
Genotyping was successful in 22 of 23 samples with viral load >1000 copies/mL, of 
which 18 samples (82%) harbored at least one clinically relevant resistance mutation in 
the RT gene. The most frequent mutations were: M184I/V (n=14), conferring resistance 
to lamivudine/emtricitabine, and K103N (n=6), Y181C (n=6) and G190A (n=6), 
conferring resistance to NNRTIs. Fourteen patients had dual-class resistance, i.e. 
resistance to both NRTIs and NNRTIs. Thymidine analogue mutations (TAMs), 
associated with broad cross-resistance to NRTIs, were found in 5 patients. In total, 18 of 
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212 patients (8.5%) harbored drug resistance by use of a standard genotyping assay. The 
prevalence (95% CI) of any clinically significant drug resistance after 1, 2, 3 and 4 years 
was 3.9% (0.8-11.0), 8.4% (3.5-16.6), 16.7% (6.4-32.8) and 12.5% (1.6-38.3), 
respectively. Only duration of ART was significantly associated with emergence of drug 
resistance (3 years vs. 1 year on ART; odds ratio [OR] 4.49; 95% CI 1.13-17.8; 
P=0.033). 
 
We concluded that virological suppression rates were good up to 4 years after starting 
ART; however, of concern, drug resistance increased with time.  
 
4.3. Paper III: Dried Blood Spots perform well in viral load 
monitoring of patients who receive antiretroviral treatment in 
rural Tanzania 
This paper aimed to compare HIV-1 RNA viral loads from DBS with results of a plasma-
based method. We obtained 98 plasma-DBS pairs from patients on ART, with plasma 
viral loads ranging from undetectable to >1,000,000 copies/mL. In a linear regression 
model there was a strong correlation between HIV-1 RNA levels in plasma and DBS, 
with a slope of 0.76, an intercept of 0.69, and an R2 value of 0.75. HIV-1 RNA levels 
were, on average, slightly higher in plasma compared to DBS, but mean difference was 
only 0.04 log10 (SD 0.57). Eight samples yielded more than 1 log10 difference between 
plasma and DBS values. 
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Sensitivity using DBS was reduced in samples with low-level viraemia. In samples with 
plasma viral loads ranging from 40 to 1000 copies/mL, only 2 of 28 (7%) had detectable 
HIV-1 RNA in DBS. On the contrary, all 27 samples with plasma viral loads 3000 
copies/mL had detectable HIV-1 RNA in DBS.  
 
The ability of DBS to detect major virological failure (5000 copies/mL) was assessed 
using ROC curves. Area under the ROC curve was 0.97, indicating that DBS had strong 
diagnostic properties. The optimal DBS threshold appeared to be at 5000 IU/mL, giving a 
sensitivity, specificity, positive predictive value and negative predictive value of 0.91, 
0.97, 0.79 and 0.99, respectively (assuming 10% major virological failure). Ninety-four 
of 98 plasma/DBS pairs (96%) showed concordant results. 
 
We concluded that DBS performed well in viral load quantification of patients on ART in 
rural Tanzania, even though sensitivity was reduced in patients with low-burden 
viraemia.  
 
4.4. Paper IV: HIV type-1 drug resistance testing on dried 
blood spots is feasible and reliable in patients who fail 
antiretroviral therapy in rural Tanzania 
This paper aimed to compare genotypic resistance results from DBS with those of 
plasma. We included 36 ART-experienced individuals with treatment failure (viral load 
>1000 copies/mL) and an available plasma genotype. HIV-1 pol was successfully 
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amplified in 34 of 36 (94%) corresponding DBS specimens. The two DBS specimens 
which could not be amplified both had low-level viraemia: 1432 copies/mL and 2621 
copies/mL. 
 
Among 34 plasma/DBS pairs, the mean nucleotide similarity was 98.1% (SD 0.87). In 
the protease region, 142 mutations were detected in plasma, of which 132 (93%) were 
also found in DBS. Five protease mutations were detected in DBS only, all of which were 
amino acid mixtures with the wild-type strain. All the plasma-derived protease mutations 
were minor mutations or polymorphisms, and none of the patients harbored resistance to 
protease inhibitors. In the RT region, however, 57 clinically significant mutations were 
found in plasma, of which 51 (89%) were also detected in DBS. Four of the 6 RT 
mutations that were missed in DBS were from patients with early treatment failure (viral 
load 3000 copies/mL). Two RT mutations were detected in DBS only, but both were 
amino acid mixtures in the 184 position with the same clinical interpretation: M184IMV 
in DBS and M184V in plasma. Thirty of 34 (88%) patients had identical resistance 
profiles to antiretroviral drugs in plasma and DBS, according to the Stanford 
interpretation.  
 
In conclusion, genotyping from DBS was successful in the vast majority of samples, and 
there was a high concordance between mutations found in plasma and DBS. 
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5. Discussion
Although a number of ART studies have been conducted in sub-Saharan Africa over the 
past few years, there is still a paucity of research from rural settings. The scale-up of 
ART in resource-limited settings began in larger urban centres [32-34, 36, 92], and still 
services to rural populations lag behind [93]. Rural ART programs face a number of 
additional challenges, such as shortages of healthcare personnel, transport difficulties and 
other logistical constraints, and experiences from well-run clinics in Cape Town or 
Lusaka are not necessarily generalizable to rural Tanzania. The present study is one of 
few to report results from a routine ART clinic in rural Africa, and we believe our 
findings better reflect the realities in such settings. 
 
In the first part of this study we assessed overall program performance, including 
mortality, viral suppression and emergence of drug resistance. We found a very high 
mortality in this cohort, particularly the first months after initiating ART, which at least 
partly could be explained by advanced immunodeficiency at baseline. On the other hand, 
among patients who survived the first 6 months and remained in care, long-term 
virological suppression rates were good and the overall prevalence of drug resistance was 
relatively low. Our results suggest that long-term benefits of ART can be sustained in 
rural Tanzania, but treatment should be initiated before patients have developed AIDS. 
Furthermore, we sought to identify clinically useful predictors of mortality, so that 
patients at particularly high risk could be identified at an early stage. Anemia, 
malnutrition and thrombocytopenia were strong and independent predictors of mortality 
in our cohort. A prognostic model based on hemoglobin level appeared to be useful for 
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initial risk assessment, and can be of particular use in settings without access to CD4 cell 
counts.  
 
In the second part of the study we aimed to find a solution to one of the most pressing 
problems we encountered in our setting: the lack of field-friendly assays for viral load 
quantification and drug resistance testing. The use of DBS could simplify blood 
collection and shipment, and in our study there was a good agreement between viral load 
levels in DBS and plasma, although DBS had reduced sensitivity in samples with low-
level viraemia. Furthermore, in patients with treatment failure, resistance genotyping was 
successful in the vast majority of DBS specimens, and there was high concordance 
between mutations found in DBS and plasma. Our study suggests that DBS can be a 
feasible and reliable tool to monitor viral load and drug resistance in patients on ART in 
resource-limited settings. 
 
In the following I elaborate on our main findings, their strengths and weaknesses, and 
their consequences for clinical practice.  
 
5.1. Sample and representativeness 
An important question is: How representative are our findings? Haydom Lutheran 
Hospital is an old mission hospital which has benefited from support from Norway for 
more than 5 decades, and as such might not be representative of all rural hospitals in 
Tanzania. Certain advanced equipment available in Haydom, such as computer 
tomography for suspected cerebral toxoplasmosis, is definitely unavailable in most rural 
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hospitals in the country. Furthermore, reliable CD4 cell counts were available already in 
2006, at a time when this was rare in other rural hospitals.  
 
On the other hand, the patients included in our study, in an area where the majority rely 
on subsistence farming and pastoralism, are typical of rural Africa. Furthermore, Haydom 
Lutheran Hospital is faced with the same logistical challenges as other rural hospitals in 
the country due to its remote location and high patient load. Although the hospital is 
church-owned, the HIV program in Haydom is fully integrated in the National AIDS 
Control Program at the Ministry of Health and Social Welfare. Moreover, approximately 
half of the hospital beds and rural health services in Tanzania are operated by churches, 
and thus, being a church-owned hospital is not atypical. 
 
Obviously, hospitals in Tanzania and Africa differ hugely, and our findings are not 
necessarily applicable to all locations. However, we believe that our data better represent 
the situation in rural Africa than studies carried out in larger urban centres.    
 
5.2. Mortality
We found a very high mortality in this cohort, with an estimated 1 year mortality of 29%. 
The majority of deaths occurred within 3 months of starting ART. Other studies from the 
region have also reported high early mortality; indeed, in a review article from 2008 
Lawn and colleagues reported that between 8 and 26% of patients in sub-Saharan Africa 
die in their first year of ART, of whom the majority die in the first few months after ART 
initiation [94].  
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 The higher mortality in our study compared to many other studies could have several 
explanations. First, being a hospital-based study, there was probably a bias towards more 
severe disease at baseline in our study compared to out-patient programs. Furthermore, 
this was the first ART program in the area, and in the early days of the program we might 
have included a “pool” of patients with severe AIDS, who thereby contributed to the 
poorer overall survival. Finally, we initiated ART in all eligible patients regardless of 
presumed prognosis, as opposed to certain other studies that excluded patients with active 
opportunistic infections, laboratory abnormalities or presumed poor adherence [95]. 
Moreover, some studies had a lengthy (4 weeks to 4 months) patient preparation process 
between enrolment and ART initiation, and consequently many of the most severely ill 
patients died pre-ART and did not contribute to on-treatment mortality [31, 33, 39]. Such 
a strategy gives a skewed impression of program performance.  
 
The high early mortality rates in sub-Saharan Africa probably reflect advanced 
immunodeficiency at baseline. In our study, more than half of the patients had clinical 
AIDS at enrolment. In the ART-LINC collaboration (Antiretroviral Treatment in Lower 
Income Countries) the median CD4 cell count at ART initiation in sub-Saharan Africa 
was 111 cells/μL and 62% had advanced disease (WHO stage 3 or 4) [96]. By contrast, 
patients from Europe and North America in the ART-CC study (Antiretroviral Treatment 
Cohort Collaboration) initiated ART with a median CD4 cell count of 224 cells/μL and 
only 23% had advanced disease (CDC stage C) [97]. Our results and results from the 
ART-LINC study underscore the need to identify HIV-infected individuals and start 
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treatment earlier in the course of their illness. Likewise, as the majority of HIV-infected 
individuals are unaware of their HIV status [93], it is necessary to increase the 
availability and uptake of HIV testing and counselling services. Once patients have 
enrolled into HIV care, health system delays before ART initiation should be minimized. 
Indeed, in a recent study from sub-Saharan Africa, Brinkhof and colleagues showed that 
excess mortality is moderate and reaches that of the general population in the second year 
of ART, among HIV-infected individuals who initiate ART before severe 
immunodeficiency has developed, i.e. with less advanced disease and a CD4 cell count 
above 200 cells/μL [22]. 
 
We found that baseline anemia, malnutrition and thrombocytopenia were strong and 
independent predictors of mortality. Previous studies have also reported that anemia [32, 
36, 98-101] and malnutrition [31, 35, 36, 102-105] predicts mortality, both in high-
income and low-income countries. A new and important finding of our study, however, 
was that a prognostic model based on hemoglobin level appeared to be a particularly 
useful tool for initial risk assessment. By categorizing the patients according to baseline 
hemoglobin, we were able to distinguish between patients at low, low intermediate, high 
intermediate and high risk of death. Previously, Mocroft and colleagues have reported 
similar findings in European HIV patients, even after adjusting for CD4 cell count and 
viral load level [100]. Recently, studies from Côte d’Ivoire, South Africa and Malawi 
have confirmed the usefulness of hemoglobin level in prognostic models in African HIV 
patients [106, 107]. In our study, patients with a hemoglobin level below 8 g/dL had 
approximately 40% risk of death within 3 months of ART initiation. It is likely that these 
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early deaths were caused mainly by conditions preexisting at enrolment and/or by 
immune reconstitution syndrome [94]. Hence, in settings with limited resources, baseline 
hemoglobin level could be used to identify patients at high risk who would need a more 
targeted search for opportunistic infections and a closer follow-up. On the opposite, time 
and resources could be released by a less rigorous follow-up of patients at low risk. 
Hemoglobin is a cheap and simple laboratory test, and could be a particularly useful tool 
in settings without access to CD4 cell counts.  
 
There were some weaknesses of our study. First, attrition rates were high: 10.9% were 
transferred out and 9.7% were lost to follow-up. It is likely that many of the patients 
classified as lost to follow-up in reality died, and thus the overall number of deaths is 
probably underestimated. The true mortality rates in this cohort could therefore be even 
higher than reported in our study.   
 
The high attrition rates could also have affected the Cox proportional hazards models 
used to identify predictors of mortality. Patients lost to follow-up were censored at their 
last clinic visit, but if mortality was higher in individuals whose follow-up time was 
censored than it was in otherwise identical individuals whose follow-up time was not 
censored (termed informative censoring), then our results could be biased [88]. In a 
recent study on determinants of survival among patients on ART in Uganda, the authors 
found that not accounting for losses to follow-up led to identification of spurious 
associations and missed actual relationships [108]. Although losses to follow up in the 
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Ugandan study (22.9%) were much higher than in ours (9.7%), we can not exclude that 
our results were affected by a similar bias.  
 
Furthermore, we lacked CD4 cell counts and HIV viral loads, which are important 
predictors of mortality in patients on ART [20]. The lack of these variables in the final 
Cox model might have impaired the generalizability of our results [109]. Nevertheless, 
our study suggests that alternative markers could be used for initial risk assessment in the 
absence of CD4 cell counts and viral loads. 
 
Finally, we did not have reliable information on death causes, which would have been a 
nice addition to this study. Available studies from sub-Saharan Africa suggest that 
tuberculosis, cryptococcal meningitis, sepsis, Kaposi’s sarcoma and wasting syndrome 
are the leading causes of death after ART initiation [94]; however, data are limited. 
Moreover, we did not systematically register toxicities of antiretroviral drugs. The long-
term use of stavudine is a concern in resource-limited settings [37, 49, 110], and a 
systematic screening for lipodystrophy and neuropathy would be of interest in a cohort 
like ours. Future studies should aim to include this information. 
 
5.3. Virological failure and resistance 
Among patients alive and in care, virological suppression rates were good up to 4 years 
after initiating ART. In fact, our results with viral suppression in 94.8%, 88.0%, 75.0% 
and 87.5% of patients after 1, 2, 3 and 4 years, respectively, were comparable to results 
from the ART-CC study, in which 78% of patients in North America and Europe were 
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virologically suppressed after 3 years on ART [111]. Other studies from sub-Saharan 
Africa have usually had shorter observation time, but a few reports on long-term 
virological efficacy support our findings: a study from Senegal found viral suppression in 
approximately 70% after 2-3 years on ART [112], whereas a study from Botswana 
reported viral suppression in approximately 90% of patients throughout 5 years of 
observation [113]. Furthermore, a recent study from Khayelitsha township in South 
Africa found viral suppression in 83.8% after 5 years on ART [114]. It should be noted, 
however, that results from study settings might be better than results from routine ART 
programs, and therefore, more studies like ours are needed from routine clinical settings 
in rural Africa. 
  
A key question in the global scale-up of ART is: Does drug resistance develop more 
rapidly in resource-limited settings than in industrialized countries? In our study we 
found that emergence of resistance increased with time and reached about 15% after 3-4 
years on ART. A few other studies from sub-Saharan Africa have reported long-term 
resistance results. An early study from Senegal reported 12.5% resistance after a median 
of 30 months on ART [112], whereas a study from Côte d'Ivoire found 22% resistance 
after a median of 37 months [115]. For comparison, a study from Canada found drug 
resistance in 20% of patients after 30 months of treatment with 
stavudine/lamivudine/nevirapine, the regimen most widely used in resource-limited 
settings [116]. Furthermore, in a routine clinical setting in the UK, 19% harbored drug 
resistance after 4 years on ART [55]. An important conclusion of our study, therefore, is 
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that resistance seems to occur at a similar rate in rural Tanzania as in high-income 
countries. 
 
Of concern, we found TAMs, associated with broad cross-resistance to NRTIs, in 23% of 
patients with treatment failure. Given the lack of routine viral loads in our program, it is 
likely that many of the patients had been treated with a failing ART regimen for months - 
or even years – before the survey, and prolonged exposure to a failing regimen is a 
known risk factor for accumulation of resistance mutations [60-62]. A much cited study 
by Phillips and colleagues used a computer simulation model to show that viral load 
monitoring of patients on ART in resource-limited settings only gives a slight survival 
benefit compared to clinical monitoring [117]. Some have used this article to argue that 
viral load monitoring is unnecessary; however, the same study also found that 
accumulation and transmission of resistance mutations occur more frequently in patients 
without viral load monitoring. More recently, a large meta-analysis found that emergence 
of TAMs, as well as other resistance mutations, was significantly more common in 
patients without access to regular viral load monitoring [118]. Hence, there is a need for a 
simple, affordable viral load assay adapted for use in tropical environments, so that 
treatment failure can be detected before multiple mutations occur. 
 
In our study only duration of ART was significantly associated with drug resistance. 
Patients who had received ART for 3 years had more than 4-fold increased risk of 
harboring drug-resistance mutations compared to patients on ART for 1 year. This is in 
line with studies from Europe and North America [55, 119]. Moreover, we observed a 
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strong, but only borderline significant, association between baseline anemia and 
lymphopenia and emergence of resistance. This association should be confirmed in larger 
studies, but it might reflect the previously reported increased risk of drug resistance in 
patients who initiate ART with advanced immunodeficiency (high viral load and low 
CD4 cell count) [119]. Unfortunately, we lacked data on adherence, which is considered 
the major determinant of drug resistance in patients on ART [119]. 
 
Although overall results from our study were encouraging, with good virological 
suppression rates and moderate emergence of resistance, the economical and logistical 
consequences of treatment failure and drug resistance in resource-limited settings are 
considerable. With more than 5 million individuals currently receiving ART in low- and 
middle-income countries, 15% with drug resistance after 3-4 years of treatment, as 
observed in our study, translates into 750,000 patients in need of second-line ART within 
a few years. At present the cheapest WHO recommended second-line regimen 
(atazanavir/ritonavir + tenofovir/lamivudine) costs at least 7 times more than the cheapest 
first-line regimen [41]. Furthermore, the pill burden increases to at least 4 tablets daily, 
which might come in addition to treatment for tuberculosis or other opportunistic 
infections, and a high pill burden is associated with reduced adherence [120]. Our results 
suggest that funding for ART programs will have to increase substantially over the 
coming years in order to meet the increasing demand for second-line regimens. 
Moreover, newer antiretroviral drugs should be made available at affordable prices for 
patients who need third-line regimens, and new fixed-dose combination tablets should be 
developed in order to reduce pill burden and promote adherence.  
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 There were certain limitations of the present study. Most importantly, as this was a cross-
sectional virological survey of patients alive and in care, we left out patients who were 
transferred out, lost to follow-up, died or who discontinued treatment. Among patients 
who discontinued treatment (4.9%) or were lost to follow-up (8.4%), there was probably 
a substantial proportion who harbored drug resistance. Patients who were transferred out 
when ART became available through the public sector, however, did probably not differ 
significantly from those who remained in care. Among patients who died, the majority 
died within a few months of starting ART, most likely due to advanced disease at 
baseline rather than drug resistance. Our analysis, therefore, must be considered an on-
treatment analysis, and results from an intention-to-treat analysis, which is often used in 
clinical trials, would have been poorer. However, our study is one of the first to provide 
information about long-term virological efficacy of ART in a rural African setting, and 
might provide a useful forecast of drug resistance and demand for second-line 
antiretroviral drugs in rural Africa in the coming years.  
 
Another limitation of our study is that we based our viral load results on a single blood 
test. Viral load can increase during intercurrent illnesses or due to random biological and 
statistical variations (“blips”). Many studies define treatment failure as two consecutive 
viral loads above a set level, which is more robust to random variations. The use of a 
single viral load measurement in our study might therefore have led to a slight 
overestimation of virological failure; however, “blips” above 400 copies/mL, the failure 
threshold in our study, are rare [121]. 
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With regard to the prevalence of drug resistance, our results might have been 
underestimated by selection and misclassification bias. Firstly, three patients who were 
already on second-line ART at the time of the survey were excluded since genotypic 
resistance results prior to the regimen switch were unavailable. Two of these had 
confirmed virological failure prior to the switch, whereas the third patient had dubious 
clinical failure without virological confirmation. Secondly, two patients with low-level 
viraemia (400-1000 copies/mL) and one patient whose genotyping failed were assumed 
not to harbour resistance. In the worst case, if all these six patients harbored drug-
resistance mutations, the overall proportion with drug resistance would be 24 of 215 
patients (11.2%), and the prevalence of drug resistance after 1, 2, 3 and 4 years would 
increase to 3.9%, 10.7%, 24.3% and 17.6%, respectively. 
 
Since we lacked longitudinal virological data, we could not exclude that resistance was 
present pre-ART. However, Haydom Lutheran Hospital was the first centre to offer ART 
in the area, and it is unlikely that any of the patients had been exposed to previous ART. 
Transmitted resistance is still very rare in Tanzania, even in Dar es Salaam, where access 
to ART is better than in the rest of the country [122]. 
 
Finally, it is important to ask whether our virological results were reliable or not. Could 
suboptimal handling of blood samples have caused any systematic error in our results? 
HIV-1 RNA is vulnerable to degradation, and therefore, we paid strict attention to the 
manufacturer’s instructions for collection, storage and transport of specimens. The 
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temperature in the freezer at the collection site was checked daily, and although power 
supply interruptions were frequent, the hospital’s generator maintained the temperature 
constant. As described in chapter 3.3.2, we sent 7 duplicate samples without prior 
freezing to Oslo University Hospital, and found good agreement with samples stored for 
5 weeks at -20°C in Haydom and tested at Muhimbili National Hospital. Hence, we 
concluded that the viral load measurements in this study were reliable.  
 
5.4. Dried blood spots for viral load monitoring 
In our study we found a good correlation between HIV-1 RNA viral load results in 
plasma and DBS from patients on ART. Although previous laboratory studies had 
reported similarly good results [74, 78-81], our study was the first to test this method in 
real life in rural Africa, the setting where it can be of most use.  
 
Since the onset of our study, a number of other research groups have assessed the use of 
DBS for viral load quantification [123-138]; however, only two studies used samples 
from rural clinics in Africa [131, 133]. The study by Löfgren and colleagues is of 
particular interest, since it demonstrated the programmatic efficiency of DBS-based viral 
load quantification in a low-income country. DBS samples were collected in rural 
hospitals in Tanzania and sent by ordinary mail to the reference laboratory, and - in 
contrast to other studies - testing of samples was performed in the country [131]. Our 
study, together with others, indicate that virological monitoring in resource-limited 
settings now can be within reach. 
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However, there are some caveats. In DBS specimens with low viral loads (<3000 
copies/mL) we observed a reduced sensitivity to detect HIV-1 RNA. Most other DBS 
studies have reported a detection limit around 1000 copies/mL, ranging from 
approximately 250 [80] to 5000 copies/mL [126]. For comparison, commercial plasma-
based viral load assays can reliably quantify HIV-1 RNA down to 20-50 copies/mL. 
These ultrasensitive assays usually require an input volume of approximately 1 mL of 
plasma, equivalent to 2.5 mL of whole-blood. DBS consist of small volumes of whole-
blood; each circle of a 903 filter paper card holds 75-80 μL of whole-blood when 
saturated [139]. The input volume to the nucleic acid amplification, therefore, is 
markedly reduced when DBS are used rather than plasma, and DBS-based HIV-1 RNA 
quantification can never achieve the same sensitivity as standard plasma-based methods. 
Nonetheless, further refinement of DBS-based methods could increase sensitivity to a 
satisfactory level. 
 
We used the NucliSens EasyQ HIV-1 assay to measure viral load in DBS. This assay 
uses an isothermal transcription-based amplification system designed specifically for 
RNA detection [140-142]. In the absence of heat denaturation, double-stranded DNA can 
not participate in the amplification process. This is not relevant when plasma is used 
since plasma only contains cell-free RNA; however, when DBS are used for viral load 
quantification, proviral DNA from peripheral blood mononuclear cells can contribute in 
the amplification process. This might explain why some studies have reported an 
overestimation of viral load levels in DBS from patients with low-level viraemia (<5000 
copies/mL in plasma). This phenomenon was observed in two studies using the Generic 
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HIV Charge Virale assay (Biocentric, Bandol, France) [135, 137], two studies using the 
m2000rt Real-Time HIV-1 assay (Abbott Laboratories, Abbott Park, IL, USA) [131, 
132], and one study using the Cobas TaqMan Real-Time RT-PCR assay (Roche 
Diagnostics) [138]. All these assays are based on RT-PCR, which amplifies all nucleic 
acid material in the sample. Thus, a positive amplification result could be caused by 
either RNA or DNA or both. The contribution of proviral DNA to the viral load result 
was recently confirmed by Monleau and colleagues, using the Generic HIV Charge 
Virale assay: DBS treated with DNase yielded significantly lower viral loads than DBS 
tested in the absence of DNase [136]. However, the presence of HIV-1 DNA in a patient 
sample does not imply treatment failure, and joint amplification of RNA and DNA can 
lead to serious problems in the interpretation of a positive result. Studies using the 
NucliSens assay, on the contrary, did not report overestimation of HIV-1 RNA levels. 
NASBA technology, therefore, appears to be particularly suitable when DBS are used 
instead of cell-free plasma for HIV-1 RNA quantification.  
 
A weakness of our study was that we used different viral load assays for plasma and 
DBS. Assay choice for plasma was based on availability in Tanzania, but we 
acknowledge that it would have been methodologically sounder to use the same assay for 
plasma and DBS. However, previous studies have found good agreement between the 
NucliSens and the Amplicor assay, although NucliSens on average gave slightly lower 
results than Amplicor [87, 143]. In fact, the scatter plots and regression analyses in these 
two studies, with an R2 value of 0.75 and 0.7997 using plasma with both assays, were 
quite similar to our results (R2 = 0.75). Amplicor gives viral load results as copies/mL 
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and NucliSens as IU/mL, but according to the manufacturer these are equivalent in 
version 1.2 of the NucliSens assay. 
 
We used linear regression to compare HIV-1 RNA levels in plasma and DBS. Linear 
regression does not require normally distributed data; however, a prerequisite is that the 
dependent variable is continuous, which was fulfilled in our study [88]. In our data set, 33 
plasma values and 61 DBS values were negative or below the lower limit of detection. 
For the purpose of analysis, these samples were reported at the cutoff value of the assay, 
which according to the manufacturer is 40 and 400 copies/mL for the TaqMan and 
Amplicor, respectively, when plasma is used. For the NucliSens assay using DBS, 
however, the lower limit of detection has not been established, and we chose 250 IU/mL 
as the cutoff value based on the lowest positive measurement in our study (280 IU/mL). 
This decision might have affected the regression line and the mean difference between 
the assays; however, the contribution of this was limited, and the strong correlation 
between plasma and DBS results remained after excluding results below the detection 
limit. 
 
5.5. Dried blood spots for resistance testing 
In our study we achieved a HIV-1 genotypic resistance result in 94% of DBS from 
patients with treatment failure, and there was good agreement with genotypes derived 
from plasma. Prior to the onset of our study there was only one publication on the use of 
DBS for HIV-1 resistance testing [82], but over the past three years several other research 
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groups have demonstrated the efficiency of this method [86, 130, 136, 144-151]. 
However, all other studies were carried out under standardized laboratory conditions, and 
we were the first to employ this method in a routine ART program in rural Africa. 
 
We used an in-house method for genotyping, as did the majority of other studies to date. 
Commercial genotyping kits have several advantages over in-house assays, including 
quality-controlled reagents, standardized protocols and validated interpretation tools, 
which would facilitate routine use in high-throughput settings. However, the reduced 
sensitivity in samples with low viral load needs to be addressed before they can be 
recommended for clinical use. For example, Youngpairoj and colleagues, using the 
ViroSeq assay (Abbott Molecular), reported that only 8% of DBS could be genotyped 
when viral load was below 10,000 copies/mL, compared to 81% when viral load was 
above 10,000 copies/mL. When samples were re-tested with an in-house RT-nested PCR 
assay, however, 95% of samples were successfully genotyped [150]. Overall 
amplification success rates with in-house assays range from 83% to 100% [82, 86, 136, 
144, 145, 149, 151], compared to 38.6% to 83.3% for the ViroSeq assay [130, 146, 148, 
150] and 78.8% for the TruGene HIV-1 genotyping assay (Siemens Healthcare 
Diagnostics, Deerfield, IL, USA) [147]. Hence, in-house RT-nested PCR assays appear to 
be more efficient than commercial assays when DBS are used instead of plasma. 
 
DBS consist of whole-blood, and cell-associated proviral DNA can be present in the 
nucleic acid sample. Some studies amplified DBS extracts in the absence of reverse 
transcriptase to assess whether proviral DNA contributed significantly to the 
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amplification product [82, 86, 144, 148, 151]. In these studies, the presence of proviral 
DNA was demonstrated in 33-80% of RT-PCR positive DBS samples. More recently, 
Monleau and colleagues reported that amplification efficiency from DBS was markedly 
reduced in samples treated with DNase, confirming that proviral DNA contributes 
significantly to the genotypes derived from DBS [136]. Of note, this latter study found 
that the relative contribution of DNA appeared to increase with duration of DBS storage, 
indicating that RNA might be degraded at a faster rate than DNA.  
 
The interference of proviral DNA may vary according to treatment status and viral load 
level. In patients who fail treatment, more drug-resistance mutations tend to be detectable 
in plasma than in peripheral blood mononuclear cells, particularly when viral burden is 
low [152, 153]. On the contrary, in patients who interrupt treatment, proviral DNA can 
act as an archive of resistance mutations, and DBS might provide more information than 
plasma in such patients [153]. Most DBS studies to date, however, reported a high 
concordance between plasma-derived and DBS-derived sequences. Nucleotide similarity 
between the two sample types ranged from 98.1% [154] to 99.9% [144]. Drug-resistant 
mutations found in plasma were detected in 82% [86] to 100% [146, 147, 151] of the 
corresponding DBS specimens. Few additional mutations were detected in DBS, and 
those found were mainly as amino acid mixtures with the wild-type strain. 
 
Two studies reported a significant discrepancy between genotypes derived from DBS and 
plasma. Buckton and colleagues observed several amino acid differences in paired 
plasma and DBS specimens [145]. However, the sample size was small (n=12), and only 
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two patients had clinically significant drug resistance; in both cases the plasma and DBS 
genotypes were discordant. Furthermore, Steegen and colleagues reported a lack of 
reproducibility for the detection of drug-resistant mutations in DBS, but this study 
specifically sequenced DNA and can not be compared directly to other studies which 
include an RT-PCR step [149]. By contrast, two studies reported a high degree of 
reproducibility from DBS specimens, with a mean nucleotide sequence concordance of 
99.2% and 99.76% for the set of DBS replicates, using the commercial TruGene assay 
and an in-house assay, respectively [144, 147]. 
 
The main limitation of our study was the sample size. Ideally we should have included 
more than 36 plasma/DBS pairs for comparison, but the overall low rates of treatment 
failure in the program, although fortunate for the patients, limited the number of samples 
available for comparison.  
 
Further, we were unable to assess the effect of different environmental conditions on the 
ability to genotype HIV-1 from DBS. However, other laboratory studies have assessed 
specific storage conditions in detail. Our aim was to assess how a DBS-based monitoring 
strategy would perform under field conditions, i.e. with storage at non-standardized 
ambient temperature for various lengths of time, which is closer to how the method 
would be applied in real life.  
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5.6. Could dried blood spots expand access to virological 
monitoring in resource-limited settings? 
Our results could have direct implications for monitoring of HIV-infected individuals in 
resource-limited settings. The question is whether DBS are sufficiently reliable to be used 
for patient monitoring in routine clinical practice.  
 
Viral load is usually measured in order to detect treatment failure and assess the need for 
second-line treatment. In resource-limited settings, where the selection of second-line 
antiretroviral drugs is scarce, the WHO recommends to conserve first-line treatment as 
long as viral load does not exceed 5000 copies/mL, because the risk of clinical 
progression is limited below this level [44, 45]. In our study, we found that DBS had 
reduced sensitivity to detect HIV-1 RNA when viral burden was low (<3000 copies/mL), 
which has also been observed by others [74, 126]. However, using a threshold of 5000 
copies/mL to define major virological failure, as recommended by the WHO, DBS 
showed high sensitivity, specificity and predictive values. Thus, DBS appear to be 
sufficiently sensitive in combination with the WHO guidelines to decide who needs 
regimen switching in resource-limited settings.  
  
With regard to resistance testing in routine clinical practice, this will become increasingly 
important as ART programs mature and more patients fail treatment. Currently, the WHO 
has no viable strategy to manage patients who fail second-line treatment [45]. In our 
study, DBS yielded a genotype in the vast majority of patients with treatment failure, and 
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there was a high concordance with plasma results. Most other studies have also reported 
good agreement with plasma, although certain theoretical caveats exist, such as the 
contribution of HIV-1 proviral DNA. The WHO, in collaboration with a network of 
international experts (HIVResNet), recently published a laboratory strategy for 
surveillance of transmitted HIV drug resistance (primary resistance in untreated 
individuals), where the use of DBS was recommended in resource-limited settings [155]. 
The WHO method using DBS has been successfully employed in surveys of transmitted 
drug resistance in Malawi, Tanzania, Iran and China [122, 156-158], and could be further 
adapted to routine use in clinical patient management. Each filter paper card contains 4-5 
blood spots, of which 2 are needed for viral load quantification, and the remaining can be 
used for resistance testing in viraemic patients. Such a monitoring strategy would be fully 
feasible, but would demand an upgrading and funding of central laboratories. 
 
5.7. Future research 
Huge operational challenges still remain in the scale-up of ART. Still only 36% of those 
estimated to be in urgent need of ART receive it [46], and research should aim to identify 
even simpler delivery systems for large-scale treatment in remote and rural areas. 
Strategies to reduce the high early mortality in ART programs in Africa must be 
identified, including how to increase uptake in HIV testing services so that HIV-infected 
individuals who are unaware of their serostatus can get access to care and treatment 
before they develop severe immunodeficiency. Surveillance of drug resistance should be 
a priority globally to ensure that the empirical first- and second-line ART regimens 
recommended by the WHO are potent and efficient. 
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 In the near future many programs will face the challenges of treatment failure and 
resistance even to second-line regimens. Viral load and resistance testing will inevitably 
become a pressing need in such settings. DBS can be a solution for viral load monitoring 
in resource-limited settings, but the method will have to be standardized and optimized 
for a high-throughput setting. Excision of blood spots and extraction of nucleic acids 
from DBS samples requires more hands-on time than automated systems designed for 
plasma samples, and carries the risk of cross-contamination. Although certain studies 
have explored simplified laboratory procedures, such as the use of a hand-held office 
hole-punch for excision of blood spots [159], there is a need for increased automation of 
the excision and extraction step to allow for mass testing in high-prevalence settings. 
Furthermore, standardization of viral load assays for DBS usage is required, and it should 
be ascertained whether there are significant differences between PCR-based and 
NASBA-based assays in patients with low-level viraemia. 
 
With regard to drug resistance testing on DBS, most studies have utilized in-house assays 
for genotyping from DBS, and there is a need for standardization and quality control of 
the protocols used by different laboratories. The WHO has developed recommendations 
for the use of DBS in surveillance of transmitted HIV drug resistance, and these can serve 
as a guide for the use of DBS in clinical patient management [155]. However, further 
research is warranted to explore the interference of proviral DNA according to treatment 
status and viral load level, as some studies have indicated possible differences between 
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plasma and DBS in early treatment failure and in patients who interrupt treatment [152, 
153]. 
 
The ideal solution for virological monitoring in resource-limited settings would be a 
simple, stable, robust and affordable point-of-care assay. This would remove the 
difficulties related to transport of samples and reporting back results, and facilitate 
immediate treatment decisions at the testing site. Rather than to force-fit high-tech 
solutions into resource-constrained health systems, research should focus on invention of 
low-tech point-of-care assays, both for HIV-1 RNA viral load quantification and drug 
resistance testing. A semi-quantitative dipstick HIV-1 RNA assay is under development 
by a research group at Cambridge University, but is not yet commercially available [160]. 
Other efforts to develop point-of-care assays are still far from materializing into available 
products. Thus, for the coming years, DBS appear to be the only viable option for viral 
load quantification and resistance testing in settings with limited laboratory capacity.  
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6. Concluding remarks 
This thesis highlights that favorable long-term virological efficacy of ART can be 
achieved in rural Africa, and that drug resistance appears to develop at the same rate as in 
high-income countries. However, the high early mortality in our study underscores the 
need to identify HIV-infected individuals and start ART earlier in the course of their 
illness. We identified anemia, malnutrition and thrombocytopenia as predictors of 
mortality, and found that a prognostic model based on hemoglobin level was particularly 
useful for initial risk assessment. 
 
In our study the use of DBS was a feasible and reliable option for viral load and 
resistance testing in rural Tanzania. It is my hope that our work will contribute to 
increased access to virological monitoring in resource-limited settings, and it is 
encouraging to notice that the newest version of the NucliSens viral load assay comes 
with a standardized protocol for DBS.   
 
Unfortunately, at the time I submit this thesis there are darks clouds in the horizon. Many 
of the large institutional donors are now reducing their contributions to ART programs, 
based on short-sighted financial considerations. At the same time, mathematical models 
have suggested that universal HIV testing with immediate ART can reverse the pandemic 
and nearly eliminate HIV by 2050 [161]. It is my sincere belief that a sustained 
commitment to the scale-up of ART, combined with continued focus on research, will be 
the only way to combat the HIV pandemic. 
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Appendix
Name                                                              Surveillance No.  
170306/JNB 
 1
HAYDOM LUTHERAN HOSPITAL - HIV TREATMENT UNIT  NCTP-ID no.:__________ 
HISTORY SHEET – INCLUSION DATE…../…../20… Date of filling form:…../…../20… 
To be used for all patients. Laboratory results from the inclusion should be entered on the space 
for baseline. For patients included before January 2005 only subsequent laboratory results after 
Jan. 2005 to be entered. Staging first column (A) to be filled in according to baseline examination. 
Age   _ and/or       Date of Birth….../….../…………        Sex   M   F    
Examiner              . 
Address Village  Ward   Division  _District ______ 
Referred from   TB   MED   SUR   MAT   PED   OPD   RCH   VCT   Other____            
Previous HIV-test Y   N   Date……/……/…………   HIV+   HIV- Lab.records seen Y   N   
First HIV+ve confirmatory test    Blood..…./….../20..…. 
Second HIV+ve confirmatory test Blood..…./….../20..… .HAVACOP No.   
Travel:  Walking Bicycle Bus/car   Travelling distance:___________km  
Marital status   Si   M Co  Sep   D   W     
Ten Cell Leader __________________           
Guardian/Contact person: Name             Relationship:_________ ______.  
Does the contact person know about your HIV status: Y   N    
Can we discuss your HIV with the contact person: Y   N    
Religion   Christian   Muslim   Traditional   Hindu   Other 
Ethnic -tribe/race:  Datooga  Iraqw  Nyiramba  Nyaturu  Nyisanzu  Sukuma  Hadzabe  
   Other tribe/race  Specify:___________________ 
Can you read?  Y   N   Can you write? Y  N  
Primary school (1-7y)       yrs  Sec. school (1-6y)___yrs  Other training       yrs               
Occupation: Farm r  Business  Governm inst  Health inst  Religious inst  Driver  Housewife  
  Other . _________________     
Patners occupation (if applicable): Farmer  Business  Governm inst  Health inst  Religious inst  
  Driver  Housewife  Other .________________      
Socioeconomic situation: Selfprovided.   
   Dependent on: Spouse   Parents. Childr.. Other family   
     Crops  Other  Specify:_________ 
Sexual partner(s): No. present(last 6 months)?: ____No. lifetime?: ______  
For women – Pregnant? Y   _____weeks  N     Number of children:  total:     __alive:______           
 Years of birth for living children_____________________________  
 Breastfeeding Y   _____months  N      
Any other known PLWH/A in the family(alive):     Number:_____ 
Other members of your family dying from HIV/AIDS: ___________________________Number:_____  
Name                                                              Surveillance No.  
170306/JNB 
 2
MEDICAL HISTORY 
 Any Tuberculosis or chronic cough in the family     _____            . 
History of TB in patient:  Never had TB  
- Previous TB Pulmonary No  Y  AFB+   AFB÷   Unknown   Date(s)  _____ 
           Extrapulmonary  Location     Date(s) ___________ 
- Within last year TB: No  Y   Pulmonary AFB+   AFB÷   Unknown Date(s)          ______ . 
           Extrapulmonary  Location:     Date(s) ___________   
Are you on treatment for tuberculosis N Y  Start date:___/___/___  
      Intensive phase Y  Continuation phase Y 
 Blood transfusion.(year)   Y            N    Allergy Y   N                       . 
Hospitalisations (month)/ year/ diagnosis        . 
Other diseases/ description          
  CURRENT POSSIBLY HIV RELATED SYMPTOMS (specify on provided line) 
Yes No      (Y= yes, N= no) 
    Fever 
  Chronic fever and weakness  > 1 month  Duration______
    Weight loss. If yes: > 10 %? Y  ____kg/______ months  <10 %? Y   If not known estimate!
    Night Sweats           _____
    Cough. If yes duration?    Productive?   _____
    Shortness of breath         _____
  Diarrhoea for less than 1 month. Duration:_________
    Chronic intermittent diarrhoea > 1 month. If yes duration?   _____
    Sore throat. If yes duration:  
  Oral thrush (candida)   
  Kaposi in mouth:__________________
     Pain (specify site)         _____
    Odynophagia (retrosternal pain on swallowing)      _____
    Nausea/ vomiting (duration)        _____
    Headache (duration)         _____
    Recurrent (probable HSV-) sores (duration) Lips  Genitals  _____
    Herpes Zoster Previous (year)     Presently  _____ 
    Encephalopathy/ Neurological symptoms:      _____ _____ 
    Recurrent RTIs/ severe infections (specify)      _____ 
    Genitourinary symptoms (specify)       _____ 
    Oedema           _____ 
    Bedridden during normal daytime due to sickness   <50%    >50%    ____ 
   Other (Skin and nail changes etc.)       _____ 
Name                                                              Surveillance No.  
170306/JNB 
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MEDICATION 
Have you ever got ARV medication? Y  N   If yes when:_______where______________ 
Present ARV medication (instituted from others)? Y  N 
Are you on drugs for opportunistic infection prophylaxis / treatment: Y  N 
If yes:  Cotrimoxazole. Specify:________________________________________________ 
  INH prophylaxis. Specify:______________________________________________ 
   INH as treatment   Rifampicin  Pyrazinamide   Ethambutol 
 Other medication taken by the patient.  Specify:________________________________________ 
________________________________________________________________________________ 
 
EXAMINATION 
Current weight ________Best/normal weight_ _______ Height  Temp   
BP  HR ___ __Head circumference (children)______cm    Oedema N + ++  +++ 
General state   Well    Wasted    Bedridden    Unconscious   
Lymphadenopathy (>1cm)   N    Neck   R    L    Axillae   R    L    Inguinal   R    L   
Mouth  N   Thrush   Kaposi  Ulce r  Hairy Leucopl  Gingivitis 
Eyes   N    Pale    Yellow    Sunken  
Skin   N    Rash    Kaposi    Other tumor /abnormalities  specify  __________________________ 
Nails  N    Fungal infection      Other   Specify___________________  
Heart   N   Abnormal     
Lungs  N   Abnormal  Chest X-ray N   
Cavity  Other abnormality  
Specify _________________________  
 
Abdomen   N   Abnormal   Hepatosplenomegaly    
Extremities/ groin   N    Abnormal    Genitals   N    Abnormal    Not examined  
Signs of new central nervous system abnormalities (Cognitive deterioration)   Y    N   
 If yes specify:_____________________________________________________________ 
Peripheral neuropathy   Y    N  
 If yes specify:_____________________________________________________________ 
Other symptoms or findings. Specify:                   _ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
(N = no, normal or negative)
Name                                                              Surveillance No.  
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STAGING (F= First examination, A= Accumulated) (Check guidelines for more exact definitions) 
 
 
ADULTS AND ADOLESCENTS  (>15 years) 
 F    A  F: First examination A:accumulated   
WHO Stage I 
    1.  Asymptomatic 
    2.  Persistent generalized lymphadenopathy 
WHO stage II 
    3.  Weight loss, <10 % of presumed body weight 
    4.  Minor mucocutaneous manifestations (papular pruritic 
eruption, seborrhoeic dermatitis, angular cheilitis, recurrant oral 
ulcers) 
    5.  Herpes zoster  
    6.  Recurrent URTI (>2 in 6 months) 
    33. Fungal nail infections 
WHO Stage III 
    7.  Weight loss, >10 % of body weight
    8.  Unexplained chronic diarrhoea, >1 month 
    9.  Unexplained persistent fever (intermittent or constant), >1 
month
    10. Oral candidiasis (thrush)
    11. Oral hairy leukoplakia
    12. Pulmonary tuberculosis (current)
    34. Tuberculous lymphadenitis
    13. Severe bacterial infections (i.e. pneumonia, pyomyositis)
    35. Acute necrotizing ulcerative gingivitis or periodontitis 
    30. Unexplained anemia (<8), neutropenia (<0.5) or chronic 
thrombocytopenia (<50) 
WHO Stage IV 
    14. HIV wasting syndrome (= combination of 7 and 8 or 7 and 9) 
    15. Pneomocystis Carinii Pneumonia 
    32. Recurrent (>2 in 6 months) severe or radiologically confirmed 
bacterial pneumonia  
    16. Toxoplasmosis of the brain 
    17. Chronic cryptosporidiosis or isosporiasis with diarrhoea > 
1month 
    18. Cryptococcosis, extrapulmonary 
    19. Cytomegalovirus disease (other than liver, spleen or lymph 
node) 
    20. HSV infection, mucocutaneous > 1 month, or visceral any 
duration 
    21. Progressive multifocal leukoencephalopathy 
    22. Any disseminated endemic mycosis (i.e. histoplasmosis,             
coccidioidomycosis) 
    23. Candidiasis of the oesophagus, trachea, bronchi or lungs 
    24. Atypical mycobacteriosis, disseminated 
    25. Recurrent non-typhoid Salmonella septicaemia 
    26. Extrapulmonary tuberculosis (excluding lymphnode tbc) 
    27. Lymphoma 
    28. Kaposi’s sarcoma 
    29. HIV encephalopathy 
    36. Invasive cervical carcinoma 
    37. Symptomatic HIV-associated nephropathy or cardiomyopathy 
    38. Atypical disseminated leishmaniasis 
CHILDREN 
 F    A 
WHO Stage P I 
   P1. Asymptomatic 
   P2. Persistent generalized lymphadenopathy 
WHO Stage P II 
   P3. Unexplained persistent hepatosplenomegaly 
   P4. Mucocutaneous manifestations (papular 
pruritic eruption, lineal gingival erythema, recurrent 
oral ulcers)  
       P5. Unexplained persistent parotid enlargement 
   P6. Extenisve HPV or mollusc. contagiosum 
   P7. Recurrent or chronic URTI (>2 in 6 months)  
   P8. Herpes zoster 
   P9. Fungal nail infections 
WHO Stage P III 
   P10. Unexplained moderate malnutrition 
   P11. Unexplained chronic diarrhoea, >14 days 
   P12. Unexplained persistent fever, >1 month 
   P13. Oral candidiasis (outside neonatal period) 
   P14. Oral hairy leukoplakia 
   P18. Recurrent (>2 in 6 months) severe or 
radiologically confirmed bacterial pneumonia 
   P33. Unexplained anemia (<8), neutropenia (<0.5) 
or chronic thrombocytopenia (<50) 
   P34. Pulmonary tuberculosis 
   P36. Lymph node tuberculosis 
   P37. Lymphoid interstitial pneumonitis 
   P38. Chronic HIV-associated lung disease 
   P39. Acute necrotizing ulcerative gingivitis or 
periodontitis 
WHO Stage P IV 
   P25. Unexplained severe wasting, stunting or 
severe malnutrion 
   P15. Extrapulmonary tuberculosis 
   P16. Other disseminated mycobacteriosis 
   P17. Candidiasis of the oesophagus, trachea, 
bronchi or lungs 
   P19. Cryptococcal meningitis 
   P20. CNS toxoplasmosis  
   P21. HIV encephalopathy 
   P22. Cerebral lymphoma 
   P23. Kaposi’s sarcoma 
   P24. Recurrent septicaemia or meningitis 
   P26. Pneumocystis carini pneumonia 
   P27. Recurrent severe bacterial infections (>2 in 6 
months), excluding pneumonia 
   P28. Chronic orolabial or cutaneous HSV (>1 
month), or visceral any site 
   P35. Cryptosporodiosis or isosporiasis with 
diarrhoea >1 month 
   P40. Cytomegalovirus infection (age >1 month) 
   P41. Disseminated endemic mycosis 
   P42. Progressive multifocal leukoencephalopathy 
   P43. Symptomatic HIV-associated nephropathy or 
cardiomyopathy 
 
In infants < 18 mos (HIV antibody positive): two or 
more of the following: 
        P29. Oral candidiasis 
        P30. Severe pneumonia 
        P32. Severe sepsis 
WHO STAGE (Date)  
  Adults  Children 
I      P I:____________      
 
II      P II: __________ 
 
III      P III: __________ 
IV      P IV:___________ 
IPaper I 
Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a 
rural hospital in Tanzania
BMC Infectious Diseases 2008, 8: 52 

BioMed Central
Page 1 of 10
(page number not for citation purposes)
BMC Infectious Diseases
Open AccessResearch article
Predictors of mortality in HIV-infected patients starting 
antiretroviral therapy in a rural hospital in Tanzania
Asgeir Johannessen*1, Ezra Naman2, Bernard J Ngowi2,3, Leiv Sandvik4, 
Mecky I Matee5, Henry E Aglen6, Svein G Gundersen6,7 and Johan N Bruun1
Address: 1Department of Infectious Diseases, Ulleval University Hospital, Oslo, Norway, 2HIV Care and Treatment Centre, Haydom Lutheran 
Hospital, Mbulu, Tanzania, 3Centre for International Health, University of Bergen, Bergen, Norway, 4Centre for Clinical Research, Ulleval 
University Hospital, Oslo, Norway, 5Department of Microbiology and Immunology, Muhimbili University of Health and Allied Sciences, Dar es 
Salaam, Tanzania, 6Research Unit, Sorlandet Hospital HF, University of Agder, Kristiansand, Norway and 7Faculty for Health and Sports, University 
of Agder, Kristiansand, Norway
Email: Asgeir Johannessen* - asgeir.johannessen@medisin.uio.no; Ezra Naman - namanezra@yahoo.com; 
Bernard J Ngowi - b_ngowi@yahoo.co.uk; Leiv Sandvik - ledv@uus.no; Mecky I Matee - mmatee@muchs.ac.tz; 
Henry E Aglen - henry.aglen@isf.uib.no; Svein G Gundersen - s.g.gundersen@sshf.no; Johan N Bruun - j.n.bruun@medisin.uio.no
* Corresponding author    
Abstract
Background: Studies of antiretroviral therapy (ART) programs in Africa have shown high initial
mortality. Factors contributing to this high mortality are poorly described. The aim of the present
study was to assess mortality and to identify predictors of mortality in HIV-infected patients
starting ART in a rural hospital in Tanzania.
Methods: This was a cohort study of 320 treatment-naïve adults who started ART between
October 2003 and November 2006. Reliable CD4 cell counts were not available, thus ART
initiation was based on clinical criteria in accordance with WHO and Tanzanian guidelines. Kaplan-
Meier models were used to estimate mortality and Cox proportional hazards models to identify
predictors of mortality.
Results: Patients were followed for a median of 10.9 months (IQR 2.9–19.5). Overall, 95 patients
died, among whom 59 died within 3 months of starting ART. Estimated mortality was 19.2, 29.0
and 40.7% at 3, 12 and 36 months, respectively. Independent predictors of mortality were severe
anemia (hemoglobin <8 g/dL; adjusted hazard ratio [AHR] 9.20; 95% CI 2.05–41.3), moderate
anemia (hemoglobin 8–9.9 g/dL; AHR 7.50; 95% CI 1.77–31.9), thrombocytopenia (platelet count
<150 × 109/L; AHR 2.30; 95% CI 1.33–3.99) and severe malnutrition (body mass index <16 kg/m2;
AHR 2.12; 95% CI 1.06–4.24). Estimated one year mortality was 55.2% in patients with severe
anemia, compared to 3.7% in patients without anemia (P < 0.001).
Conclusion: Mortality was found to be high, with the majority of deaths occurring within 3
months of starting ART. Anemia, thrombocytopenia and severe malnutrition were strong
independent predictors of mortality. A prognostic model based on hemoglobin level appears to be
a useful tool for initial risk assessment in resource-limited settings.
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Background
The introduction of highly active antiretroviral therapy in
1996 dramatically improved the prognosis for HIV-
infected patients in the industrialized world [1,2]. Until
recently, however, access to treatment has been severely
limited in developing countries, where the majority of
people with HIV/AIDS live [3]. In 2002, the World Health
Organization (WHO) issued guidelines for scaling up
antiretroviral therapy (ART) in resource-limited settings,
followed by revisions in 2003 and 2006 advocating earlier
initiation of treatment [4-6]. By December 2006, two mil-
lion people in low- and middle-income countries were
receiving ART, but this was still only 28% of those esti-
mated to be in urgent need of it [7].
Few studies have examined the effect of ART in rural
Africa, and experiences from Europe and North America
are not necessarily applicable to such settings. However,
early reports from ART programs in resource-limited set-
tings have been promising, with virological efficacy com-
parable to industrialized countries [3]. Nevertheless,
mortality has been high, particularly the first months after
initiating ART [8-15], and factors contributing to this high
mortality are poorly understood.
A better knowledge of prognostic factors would allow
closer follow-up and more targeted interventions in high-
risk patients, thus reducing excess mortality. The aim of
the present study was to assess mortality and to identify
predictors of mortality in HIV-infected patients starting
ART in a rural African hospital.
Methods
Study setting and participants
Tanzania is a low-income country in East Africa with 38.3
million inhabitants and estimated adult HIV prevalence at
6.5% [7]. Life expectancy at birth is 46.5 years, which is
estimated to be ten years lower than it would have been
without the HIV epidemic [16]. Haydom Lutheran Hospi-
tal is a 400-bed hospital in Manyara region owned by the
Evangelical Lutheran Church of Tanzania. It is the main
health care provider to a rural population of about 260
000 people, and available services include a modern radi-
ology department with ultrasonography and computer
tomography, a fairly well equipped laboratory with
microscopy, bacteriology and biochemistry, as well as
standard surgical and obstetrical services. According to a
recent population-based survey, adult HIV prevalence in
the area is 1.8% [17]. In 2002, the hospital launched a
comprehensive HIV prevention and intervention program
with emphasis on voluntary counseling and testing (VCT)
through outreach services and antenatal clinics. An HIV
Care and Treatment Centre was established adjacent to
the hospital, and from October 2003 ART was provided
free of charge to eligible HIV-infected patients. Most of the
patients enrolled were detected through VCT services in
the villages or were hospitalized patients tested on clinical
suspicion. Clinical officers, under supervision of a physi-
cian, were responsible for medical follow-up of patients.
On-site training was provided by HIV specialists from col-
laborating institutions in Norway. All patients received
pre-treatment counselling, and peer-support groups were
set up in the major villages. A community home-based
care network was established to follow-up adherence and
trace missing patients.
Patients were considered eligible for ART if they were in
WHO stage IV irrespective of CD4 cell count, WHO stage
III with CD4  350 cells/L, or had CD4  200 cells/L
regardless of clinical stage, in accordance with WHO and
Tanzanian guidelines [5,18]. However, since CD4 cell
counts measured by manual techniques were observed to
be unreliable, ART initiation was based solely on clinical
criteria (WHO stage III and IV) in most patients. In addi-
tion, ART was offered to HIV-infected pregnant and lactat-
ing women to prevent vertical transmission.
The present study is a prospective, observational cohort
study of treatment-naïve patients aged 15 years or older
who started ART in Haydom Lutheran Hospital between
October 3, 2003, and November 5, 2006. Women who
were pregnant at the time of ART initiation were excluded
from the study, as were lactating mothers in WHO stage I
or II, who started ART exclusively to prevent vertical trans-
mission. Follow-up data was collected through May 5,
2007. Patients gave written consent to participate in the
study. Ethical approval was obtained from the Medical
Research Coordinating Committee of the National Insti-
tute for Medical Research in Tanzania and Regional Com-
mittee for Medical Research Ethics in Norway.
Treatment, monitoring and endpoints
First-line treatment comprised stavudine (d4T) or zidovu-
dine (ZDV), combined with lamivudine (3TC), and either
nevirapine (NVP) or efavirenz (EFV). Regimen choice was
subject to availability, with use of a generic fixed-dose
combination of d4T, 3TC and NVP whenever possible.
Second-line treatment in case of treatment failure was not
available until December 2006. Patients with CD4  200
cells/L or WHO stage III or IV disease were given co-tri-
moxazole prophylaxis 960 mg thrice weekly or 480 mg
daily. After the initial 2 weeks of daily drug administra-
tion, antiretroviral drugs were dispensed on a monthly
basis.
A standardized form was used for the baseline evaluation,
which included socio-demographic information, medical
history, physical examination, and laboratory investiga-
tions. Clinical staging was performed using the 2003 revi-
sion of the WHO clinical staging system [5]. Routine
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clinical follow-up was scheduled every 3 months. HIV
infection was established using 2 different rapid antibody
tests. Standard hematology was measured using Sysmex
KX-21 Hematology Analyzer (Sysmex Corp., Kobe,
Japan).
The most recent laboratory results before starting ART
were generally used as baseline values. In a minority of
patients who lacked pre-treatment laboratory tests, how-
ever, results obtained within one month of ART initiation
were used. If two values were obtained within a month,
the mean was employed. Body mass index (BMI, weight in
kilograms divided by height in meters squared) was used
to assess nutritional status. Body weight was measured at
each clinic visit using the same manual scale, and height
was measured using a stadiometer mounted on the scale.
Established cutoff values for BMI were used [19]: normal
(BMI  18.5 kg/m2), mild malnutrition (BMI 17–18.4 kg/
m2), moderate malnutrition (BMI 16–16.9 kg/m2), and
severe malnutrition (BMI < 16 kg/m2). Anemia was
defined as a hemoglobin level of <12 g/dL for women and
<13 g/dL for men [20], and was classified as mild (hemo-
globin 10–11.9 g/dL for women and 10–12.9 g/dL for
men), moderate (hemoglobin 8–9.9 g/dL) or severe
(hemoglobin < 8 g/dL). Lymphopenia was defined as a
total lymphocyte count (TLC) of <1.2 × 109/L [4], and we
employed an additional cutpoint at 0.6 × 109/L to assess
severe lymphopenia. Thrombocytopenia was defined as
platelet count <150 × 109/L [21].
The main endpoint in our study was death from all causes.
Deaths were registered from hospital records or reported
through home visitors. Other outcomes were also
recorded, including patients who self-stopped treatment,
were transferred to another health facility or were lost to
follow-up. Patients who missed appointments for more
than 3 months and could not be traced by the home visi-
tor, were regarded lost to follow-up.
Statistical analysis
Patients were excluded from the study if sex, age or WHO
stage was not recorded. Date of death was registered by
home visitors; however, in 7 patients with only month
and year recorded we used the 1st of that month, and in 2
patients with unknown death date we used the last follow-
up visit. For subjects who self-stopped treatment, were
transferred out or were lost to follow-up, the date of their
last follow-up visit was used as the censoring date. Finally,
individuals alive and on ART were censored at May 5,
2007.
Kaplan-Meier models were used to estimate survival after
ART initiation, and log rank tests to compare survival
curves. Cox proportional hazards models were used to
identify independent predictors of mortality and calculate
hazard ratios. Multicollinearity was excluded using Spear-
man's correlation coefficient with a cutoff at 0.7. We per-
formed univariable Cox regression analysis for the
following baseline variables: sex, age, tribe, religion, edu-
cation level, ART start year, WHO stage, BMI, hemo-
globin, TLC, platelet count, hepatitis B, syphilis and active
tuberculosis (TB). CD4 cell counts were omitted since the
results were observed to be inaccurate. Baseline variables
significant at P < 0.05 level in univariable analysis were
included in the final multivariable model. We used SPSS
version 14.0 software (SPSS Inc., Chicago, IL, USA) to
analyze the data. All tests were two-sided and level of sig-
nificance was set at P < 0.05.
Results
Baseline characteristics
Of 779 patients enrolled into HIV care between October
3, 2003, and November 5, 2006, 320 treatment-naïve
non-pregnant adults who started ART were included in
the present study. The cohort profile is presented in figure
1. Among 334 adults who had not started ART at censor-
ing, 123 (36.8%) were lost to follow-up, 90 (26.9%) did
not meet clinical criteria for starting ART, 56 (16.8%) died
before ART initiation, 27 (8.1%) were transferred to
another health facility, and the remaining 38 (11.4%)
were still waiting to start treatment.
Patients on ART were followed for a median of 10.9
months (interquartile range 2.9–19.6). Summary statis-
tics of baseline characteristics are given in table 1. Of the
320 patients included, 223 (69.7%) were women and
median age was 35 years (interquartile range 30–43).
There were 104 patients (32.5%) who started ART in the
initial years 2003–04, 117 (36.6%) started in 2005, and
99 (30.9%) in 2006. Initial ART regimen was d4T/3TC/
NVP in 168 patients (52.5%), d4T/3TC/EFV in 58
(18.1%), ZDV/3TC/NVP in 53 (16.6%), ZDV/3TC/EFV in
24 (7.5%), ZDV/3TC/tenofovir in one (0.3%) and miss-
ing in 15 patients (4.7%). Seventy-three patients received
anti-TB treatment at inclusion or started after inclusion.
Mean BMI was 17.6 kg/m2 (standard deviation [SD] 3.1),
mean hemoglobin 10.1 g/dL (SD 2.1), mean TLC 1.4 ×
109/L (SD 0.8) and mean platelet count 266 × 109/L (SD
131).
At ART initiation, 210 patients (65.6%) had clinical AIDS
(WHO stage IV). For comparison, 401 (51.5%) of 779
had clinical AIDS at enrollment into the HIV program.
The most common WHO stage IV conditions among
patients who started ART were: wasting syndrome
(89.0%), oesophageal candidiasis (13.3%), extrapulmo-
nary TB (5.2%) and Kaposi's sarcoma (4.8%).
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Survival analysis
Overall, 95 patients (29.7%) died during the follow-up
period, among whom 59 died within 3 months of starting
ART. Thirty-five patients (10.9%) were transferred to
another health facility, 31 (9.7%) were lost to follow-up
and 7 (2.2%) self-stopped treatment. Estimated mortality
was 19.2, 24.5, 29.0, 35.2 and 40.7% at 3, 6, 12, 24 and
36 months, respectively.
In univariable analysis male sex, ART start year, WHO
stage IV, severe malnutrition, anemia, lymphopenia and
thrombocytopenia were all associated with progression to
death. No such associations were found for age, tribe, reli-
gion, education level, hepatitis B, syphilis or active TB. As
described in table 1, certain baseline values were missing
in 29 patients; hence, there were 291 patients in the final
Cox model. In multivariable analysis significant predic-
tors of mortality were severe and moderate anemia,
thrombocytopenia and severe malnutrition (Table 2). The
hazard of death was significantly reduced in those starting
ART in calendar year 2006 compared with the initial
period 2003–04.
Mortality increased with decreasing hemoglobin. Esti-
mated one year mortality was 3.7% in patients without
anemia, 20.0% in mild anemia, 37.6% in moderate ane-
mia and 55.2% in severe anemia (log rank test, P < 0.001,
Figure 2). The majority of deaths occurred early, and the
corresponding 3 months mortality was 3.7, 8.1, 26.9 and
40.4%, respectively (log rank test, P < 0.001). A similar
trend was observed with decreasing BMI. Estimated one
year mortality was 13.7% in patients with normal nutri-
tional status, 21.0% in mild to moderate malnutrition,
and 46.8% in severe malnutrition (log rank test, P <
0.001, Figure 3).
Discussion
Mortality was high in this cohort, and most of the deaths
occurred within 3 months of starting ART. Severe and
moderate anemia, thrombocytopenia and severe malnu-
trition were found to be independent predictors of mor-
Profile of the study cohort, Haydom Lutheran Hospital, Tanzania (October 2003–November 2006)Figure 1
Profile of the study cohort, Haydom Lutheran Hospital, Tanzania (October 2003–November 2006).
779 individuals in 
HIV care
703 ART-naive 
HIV-infected adults
334 not on ART
46 pregnant or PMTCT
3 with incomplete data
58 children <15 years
18 ART-experienced
320 adults who 
started ART before 
November 5, 2006, 
were included in the 
study
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tality. The high early mortality observed in our study is in
line with other similar studies from resource-limited set-
tings [8-15]. Causes of death were not investigated in the
present study; however, in a study from South Africa wast-
ing syndrome, TB, acute bacterial infections, malignancies
and immune reconstitution disease were the major causes
of death [14]. In our cohort more than half of the patients
had clinical AIDS at enrollment into HIV care, and other
African ART programs have also reported high rates of
advanced disease [8-12,14,15]. Stigma and delay in seek-
ing health care, lack of voluntary testing and counseling
services, and health system delays in referral and ART ini-
tiation are possible explanations. Thus, priority must be
given to identify HIV-infected individuals and start treat-
ment earlier in the course of their illness, before they
develop severe opportunistic infections.
Anemia was a strong predictor of mortality in our study.
Patients with severe anemia had nearly 15 times higher
risk of dying during the first year on ART compared to
those with a normal hemoglobin level. Several studies
from Europe and North America have shown that anemia
is an independent predictor of mortality in patients on
ART, even after controlling for CD4 cell count and viral
load [22-24]. Recently, studies from developing countries
have found the same association [9,13]. Indeed, in the
largest African cohort study published to date, severe ane-
mia (hemoglobin <8 g/dL) was the strongest independent
predictor of mortality in 16 198 patients receiving ART in
Zambia [13].
It is uncertain whether the association between anemia
and mortality is causal or whether anemia is rather a
marker of progressive HIV disease. It is known that the
incidence of anemia increases with progression of HIV
infection [23]. Furthermore, anemia can be a feature of
certain opportunistic diseases, like disseminated myco-
bacterial infection and parvovirus B19 [25]. Several other
etiologic factors may be involved in the development of
HIV-associated anemia, including micronutrient deficien-
cies, immunological myelosuppression, impaired eryth-
ropoietin production and blood loss from intestinal
opportunistic disease [25]. The role of iron supplementa-
tion is controversial, as some reports have suggested
adverse effects of iron excess in HIV-infected individuals
in industrialized countries [26,27]. On the contrary,
Table 1: Baseline characteristics and associated mortality among 320 HIV-infected patients starting ART in Tanzania
Characteristic Number of patients Number of Deaths
Age (years)
15–24 26 7 (26.9%)
25–34 129 39 (30.2%)
35–44 95 30 (31.6%)
 45 70 19 (27.1%)
Sex
Male 97 38 (39.2%)
Female 223 57 (25.6%)
Clinical stage
WHO stage I–II 12 1 (8.3%)
WHO stage III 98 18 (18.4%)
WHO stage IV 210 76 (36.2%)
BMI (kg/m2)a
<16 98 46 (46.9%)
16–18.4 105 23 (21.9%)
 18.5 93 14 (15.1%)
Hemoglobin (g/dL)b
<8 49 27 (55.1%)
8–9.9 108 43 (39.8%)
10–11.9 (10–12.9 for men) 104 21 (20.2%)
 12 ( 13 for men) 55 2 (3.6%)
TLC (× 109/L)c
<0.6 30 18 (60.0%)
0.6–1.1 116 32 (27.6%)
 1.2 166 42 (25.3%)
Platelet count (× 109/L)d
<150 52 24 (46.2%)
 150 261 66 (25.3%)
a24 values missing (n = 296). b4 values missing (n = 316). c8 values missing (n = 312). d7 values missing (n = 313).
WHO, World Health Organization; BMI, body mass index; TLC, total lymphocyte count.
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recovery from anemia after erythropoietin treatment has
been associated with improved survival [23,24], but high
costs limit its use in poor countries. More recently, ART
has been shown to significantly reduce HIV-associated
anemia in developed countries [28,29]; however, this has
not yet been investigated in rural Africa. Further studies
are needed to explore possible interventions against HIV-
associated anemia in resource-limited settings, including
the role of iron supplementation.
Malnutrition was another strong, independent predictor
of mortality in our study. Estimated one year mortality
was nearly 50% among patients with severe malnutrition.
Previously, studies from industrialized countries have
shown that malnutrition in HIV infection is associated
with morbidity and mortality, even after the introduction
of highly active antiretroviral therapy in the late 1990s
[30-32]. More recently, studies from developing countries
have found that malnutrition is an independent predictor
of mortality in patients starting ART [8,12,13,33]. How-
ever, it is not clear whether targeted therapy for malnutri-
tion will result in improved survival [34]. Studies of
nutritional interventions in HIV patients are urgently
needed in developing countries, where malnutrition is
often a result of poverty and food insecurity.
We found a reduced risk of death in patients starting ART
in later calendar years compared with the initial period
2003–04. A possible explanation is that many patients
with severe AIDS were included in the initial period, as
this was the first clinic to offer ART in the area. However,
since the risk reduction persisted after controlling for clin-
ical stage, we believe that it may also be attributed to
improved skills among local staff managing HIV patients.
The decline in mortality over time supports our experi-
ence that non-physician clinicians can be trained to fol-
low-up and treat HIV-infected patients.
To our knowledge, thrombocytopenia has never previ-
ously been shown to predict mortality in African patients
on ART, although a few studies from North America have
described an increased risk of disease progression and
death [35,36]. Further research is needed to confirm our
findings. WHO stage IV was not significantly associated
with mortality in our study, in contrast to previous reports
[1,8,11-14]. However, the comparison group was almost
entirely composed of WHO stage III patients, which
would weaken the statistical effect of WHO stage IV on
mortality. Furthermore, the accuracy of clinical staging is
probably quite variable in rural Africa. It is interesting that
simple and more objective indicators identified in the
present study appear to have a better predictive ability
than clinical stage.
A prognostic model based on hemoglobin level had a
strong predictive power in our study, separating the
patients into low, low intermediate, high intermediate
and high risk groups (Figure 2). Previously, similar sur-
vival curves for hemoglobin levels have been reported in
European HIV patients, although anemia occurred less
frequently [22]. Hemoglobin is a simple and inexpensive
laboratory test, which can be performed even in rural,
Table 2: Hazard ratios of mortality according to baseline variables in HIV-infected patients starting ART in Tanzania
Unadjusted Adjusteda
Baseline variables HR (95% CI) P HR (95% CI) P
Gender (male vs. female) 1.73 (1.15–2.61) 0.009 1.60 (1.00–2.57) 0.053
WHO stage (IV vs. I–III) 2.71 (1.64–4.49) <0.001 1.46 (0.81–2.65) 0.210
ART start year (vs. 2003–04)
2005 0.55 (0.35–0.87) 0.010 0.64 (0.38–1.08) 0.091
2006 0.30 (0.17–0.56) <0.001 0.40 (0.19–0.83) 0.014
BMI (vs.  18.5 kg/m2)
<16 4.17 (2.29–7.60) <0.001 2.12 (1.06–4.24) 0.034
16–18.4 1.60 (0.82–3.10) 0.168 1.27 (0.62–2.61) 0.516
Hemoglobin (vs.  12 g/dL for women and  13 for men)
<8 22.7 (5.40–95.7) <0.001 9.20 (2.05–41.3) 0.004
8–9.9 13.5 (3.28–55.9) <0.001 7.50 (1.77–31.9) 0.006
10–11.9 (10–12.9 for men) 6.21 (1.46–26.5) 0.014 4.03 (0.93–17.5) 0.063
TLC (vs.  1.2 × 109/L)
<0.6 3.58 (2.05–6.24) <0.001 1.72 (0.87–3.39) 0.117
0.6–1.1 1.10 (0.69–1.74) 0.699 0.79 (0.48–1.32) 0.371
Platelet count (<150 vs.  150 × 109/L) 2.23 (1.40–3.57) 0.001 2.30 (1.33–3.99) 0.003
aCox proportional hazards model adjusted for all variables listed in the table.
HR, hazard ratio; CI, confidence interval; ART, antiretroviral therapy; WHO, World Health Organization; BMI, body mass index; TLC, total 
lymphocyte count.
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basic clinics. We believe it can be used as a simple and
practical tool for initial risk assessment in the absence of
CD4 cell count and viral load. Such early prognostic infor-
mation would allow a more targeted search for opportun-
istic infections and closer follow-up in high-risk
individuals, thus reducing excess mortality. Although the
exact mortality figures from the present study can not nec-
essarily be applied to other populations, we believe the
concept of using hemoglobin level to identify patients
with a poor prognosis can be used elsewhere. This simple
prognostic model should be tested out in other African
settings to assess its generalizability.
There are some weaknesses of our study. First, mortality
might be underestimated, since patients lost to follow-up
probably include individuals dying at home without
being reported. Although the proportion of patients lost
to follow-up in the present study (9.7%) was comparable
to other African studies [12,13], data quality would be
improved with better cohort retention. Second, the results
might be affected by selection bias towards patients with
more severe disease, since the study was conducted in a
hospital setting. Third, some patients measured baseline
hemoglobin shortly after ART initiation, which might
have led to an overestimation of the prevalence of anemia
in patients with a ZDV-based regimen. However, post-ART
hemoglobin was only employed in a small number of
patients, and it is unlikely that this has introduced any sys-
tematic bias into the study. Fourth, it is known that the
generalizability of a prognostic system can be impaired if
important independent predictors are left out [37]. We
lacked reliable CD4 cell counts and viral loads, which are
established predictors of morbidity and mortality in
patients on ART [1]. However, our results strongly suggest
that simple and available measurements can be useful
alternative prognostic markers.
The main strength of our study is that it was carried out in
a rural African hospital with use of national staff and
inclusion of all eligible patients. Most other African ART
Kaplan-Meier survival curves according to baseline hemoglobinFigure 2
Kaplan-Meier survival curves according to baseline hemoglobin. Normal: >12 g/dL (>13 g/dL for men); mild anemia: 
10–11.9 g/dL (10–12.9 g/dL for men); moderate anemia: 8–9.9 g/dL; severe anemia: <8 g/dL.
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studies have been performed in urban areas [9-11,13-15],
in research settings with strict inclusion and exclusion cri-
teria [38], or with support from an international non-gov-
ernmental organization [8,10,12]. We believe that our
results better reflect the reality in a rural hospital in sub-
Saharan Africa, and thus may be applicable to other simi-
lar settings.
Conclusion
We found high mortality among patients starting ART in
this rural Tanzanian hospital, with the majority of deaths
occurring within 3 months of ART initiation. Many
patients enrolled with advanced immunodeficiency, and
priority should be given to identify HIV-infected individ-
uals and start ART earlier in the course of their illness.
Anemia, thrombocytopenia and severe malnutrition were
strong independent predictors of mortality. A simple
prognostic model based on hemoglobin level appears to
be a useful tool for initial risk assessment in resource-lim-
ited settings.
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Abstract
Background: Virological response to antiretroviral treatment (ART) in rural Africa is poorly described. We examined
virological efficacy and emergence of drug resistance in adults receiving first-line ART for up to 4 years in rural Tanzania.
Methods: Haydom Lutheran Hospital has provided ART to HIV-infected patients since October 2003. A combination
of stavudine or zidovudine with lamivudine and either nevirapine or efavirenz is the standard first-line regimen. Nested
in a longitudinal cohort study of patients consecutively starting ART, we carried out a cross-sectional virological efficacy
survey between November 2007 and June 2008. HIV viral load was measured in all adults who had completed at least 6
months first-line ART, and genotypic resistance was determined in patients with viral load >1000 copies/mL.
Results: Virological response was measured in 212 patients, of whom 158 (74.5%) were women, and median age was
35 years (interquartile range [IQR] 29–43). Median follow-up time was 22.3 months (IQR 14.0–29.9). Virological
suppression, defined as <400 copies/mL, was observed in 187 patients (88.2%). Overall, prevalence of ³1 clinically
significant resistance mutation was 3.9, 8.4, 16.7 and 12.5% in patients receiving ART for 1, 2, 3 and 4 years, respectively.
Among those successfully genotyped, the most frequent mutations were M184I/V (64%), conferring resistance to
lamivudine, and K103N (27%), Y181C (27%) and G190A (27%), conferring resistance to non-nucleoside reverse
transcriptase inhibitors (NNRTIs), whereas 23% had thymidine analogue mutations (TAMs), associated with cross-
resistance to all nucleoside reverse transcriptase inhibitors (NRTIs). Dual-class resistance, i.e. resistance to both NRTIs
and NNRTIs, was found in 64%.
Conclusion: Virological suppression rates were good up to 4 years after initiating ART in a rural Tanzanian hospital.
However, drug resistance increased with time, and dual-class resistance was common, raising concerns about exhaustion
of future antiretroviral drug options. This study might provide a useful forecast of drug resistance and demand for
second-line antiretroviral drugs in rural Africa in the coming years.
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Background
Access to antiretroviral treatment (ART) of HIV/AIDS has
increased substantially over the past few years throughout
the developing world. Lower prices of antiretroviral drugs
combined with political determination have given rise to
one of the greatest public health operations of our time,
spearheaded by World Health Organization (WHO), Joint
United Nations Programme on HIV/AIDS (UNAIDS) and
international non-governmental organizations (NGOs).
By December 2007, three million people were receiving
ART in low- and middle-income countries, but still this
was only 31% of those estimated to be in need of it [1].
ART programs in developing countries are now moving
from early pioneer projects to a sustained effort. Inevita-
bly, the long-term challenges of providing ART will
become increasingly evident, including late drug toxici-
ties, treatment failure and emergence of drug resistance [2-
4]. Indeed, some have argued that scaling up ART in Africa
could create widespread drug resistance [5,6]. Early
reports, however, have documented good adherence to
therapy [7] and short-term virological efficacy compara-
ble to industrialized countries [8].
Although several studies on ART efficacy in Africa have
been published, the majority have been carried out in
larger cities [9-11], often with NGO support [10,12], and
usually with short follow-up time [9,10,12]. However, the
majority of Africans reside in rural areas [13], and little is
known about the long-term effects of ART in such settings.
The key to long-term benefit of ART is sustained suppres-
sion of viral replication and avoidance of resistance [14-
16]. Our aim was to assess virological efficacy and emer-
gence of drug resistance in HIV-infected patients up to 4
years after starting first-line ART in a rural Tanzanian hos-
pital.
Methods
Study setting, participants and treatment
Tanzania is a low-income country with an estimated HIV
prevalence of 6.2% [1]. The National AIDS Control Pro-
gram started to scale up antiretroviral treatment from
2005, and by December 2007, 135,696 people were
receiving ART [1]. Haydom Lutheran Hospital is a 400-
bed hospital in Manyara region owned by the Evangelical
Lutheran Church of Tanzania. It is the main health care
provider to a rural population of about 260,000 people.
In 2002, the hospital launched a comprehensive HIV pre-
vention and intervention program, which has previously
been described in detail [17]. In brief, free treatment and
care has been offered to all HIV-infected patients since
October 2003, including free drugs and in-patient care.
Clinical officers have been trained by experienced HIV
physicians to treat and follow-up patients. The HIV pro-
gram in Haydom is now integrated in the National AIDS
Control Program.
All patients were assessed with a standardized evaluation
form at enrolment, where demographic data, medical his-
tory, clinical findings and laboratory investigations were
recorded. ART was initiated in accordance with WHO's
recommendations [18-20]: WHO stage 4 irrespective of
CD4 cell count, WHO stage 3 with CD4 £350 cells/mL, or
CD4 £200 cells/mL with any WHO stage. However, reliable
CD4 cell counts were not available until September 2006;
thus, most patients started ART based on clinical criteria
only (WHO stage 3 and 4). In addition, triple-drug com-
bination ART, and not single-dose nevirapine, was offered
to HIV-infected pregnant and lactating women, from
pregnancy week 20 till cessation of breast-feeding, irre-
spective of WHO stage and CD4 cell count, to prevent
mother-to-child transmission (PMTCT).
First-line treatment was stavudine or zidovudine, com-
bined with lamivudine, and either nevirapine or efa-
virenz. A generic fixed-dose combination of stavudine,
lamivudine and nevirapine was preferred whenever possi-
ble. Patients with CD4 £200 cells/mL or WHO stage 3 or 4
disease were given co-trimoxazole prophylaxis 960 mg
thrice weekly. Second-line treatment was available from
December 2006 and comprised lopinavir/ritonavir, dida-
nosine and abacavir. Criteria for switching to second-line
ART was virological failure as recommended by WHO (i.e.
>10,000 copies/mL) [20]; however, viral load was not
measured routinely, and only selected patients with high
clinical suspicion of failure were tested.
Nested in a longitudinal cohort study of patients consecu-
tively starting ART, we carried out a cross-sectional viro-
logical efficacy survey between November 15, 2007 and
June 6, 2008. All adults (³15 years) who had received first-
line ART for more than 6 months were considered eligible.
Patients were included regardless of previous adherence
or treatment interruptions. However, those who had
stopped ART for ³1 month and not re-started at the time
of the survey were classified as "stopped treatment" and
excluded. Furthermore, those who had already switched
to second-line ART were excluded since genotypic resist-
ance results prior to the switch were unavailable. Ethical
approval was granted by National Institute for Medical
Research in Tanzania and Regional Committee for Medi-
cal Research Ethics in Norway, and all patients gave writ-
ten consent to participate in the study.
Laboratory investigations
Standard laboratory investigations at baseline included:
Full blood cell count, erythrocyte sedimentation rate, liver
function tests, creatinine, blood sugar, hepatitis B surface
antigen and syphilis serology. Patients who started ART
were followed up with laboratory investigations every
three months. Hematology was measured using the Sys-
mex KX-21 Hematology Analyzer (Sysmex Corp., Kobe,
Japan). CD4 cell counts were available from September
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2006 using the FACSCount flow cytometer (Becton Dick-
inson, San Jose, California, USA).
Plasma specimens for virological analyses were stored at -
20°C until shipment to the reference laboratory. Manu-
facturer's instructions were followed with regard to sam-
ple collection and transport. HIV viral load was measured
at Muhimbili National Hospital, Dar es Salaam, Tanzania,
using the Cobas TaqMan 48 Analyzer (Roche Diagnostics,
Branchburg, New Jersey, USA) with a lower detection
limit at 40 copies/mL; however, due to equipment break-
down, one third of the samples were analysed with the
Cobas Amplicor HIV-1 Monitor v1.5 (Roche Diagnostics,
Branchburg, New Jersey, USA) with a detection limit at
400 copies/mL. All specimens with viral load >1000 cop-
ies/mL were sent to Ulleval University Hospital, Oslo,
Norway, for genotypic resistance testing. The ViroSeq
HIV-1 Genotyping System (Abbott Molecular, De Plains,
Illinois, USA) was used to determine HIV-1 subtype and
mutations in the protease and reverse transcriptase genes.
Only drug resistance mutations listed in the Spring 2008
update from the International AIDS Society were consid-
ered [21]. Resistance profiles to antiretroviral drugs were
interpreted according to the Stanford University HIV Drug
Resistance Database (HIVdb Program, http://hivdb.stan
ford.edu).
Statistical analysis
The main outcomes of interest were on-treatment virolog-
ical suppression and clinically significant genotypic resist-
ance. Virological suppression was defined as HIV viral
load <400 copies/mL, since this was the detection limit of
the least sensitive assay used in this study. Clinically sig-
nificant genotypic resistance was defined as HIV viral load
>1000 copies/mL and presence of ³1 drug resistance
mutation listed in the Spring 2008 update from the Inter-
national AIDS Society [21]. Duration of ART was rounded
off to the nearest full year (1, 2, 3 or 4 years) when pre-
senting prevalence of virological suppression and drug
resistance. Logistic regression was used to study associa-
tions between baseline characteristics and emergence of
drug resistance. Univariable analysis was performed for
the following variables: Sex, age, WHO stage, initial ART
regimen, duration of ART, body mass index, hemoglobin
level and total lymphocyte count. CD4 cell counts were
excluded because of too few observations. Variables with
P < 0.1 in univariable analyses were advanced into a mul-
tivariable regression analysis, using the forward stepwise
(Wald) method to avoid overcorrection. Multicollinearity
was excluded using Spearman's correlation coefficient
with a cutoff at 0.7. Data were analysed with SPSS version
16.0 for Windows (SPSS Inc., Chicago, Illinois, USA),
except 95% confidence intervals (CI) for proportions
which were calculated with NCSS version 2007 (NCSS,
Kaysville, Utah, USA). All tests were two-sided and level of
significance was set at P < 0.05.
Results
Baseline characteristics
Out of 549 adults who enrolled in the HIV program and
started ART, 126 patients (23.0%) died, of whom 76 died
within 3 months of starting ART. Seventy-nine patients
(14.4%) were transferred to another health facility, 46
(8.4%) were lost to follow-up, whereas 27 patients (4.9%)
self-stopped treatment after receiving ART for a median of
11.3 months. Fifty patients were not eligible for the viro-
logical survey because they had taken ART for less than 6
months, and 3 because they were on second-line ART.
Among the remaining 218 patients who were selected for
the survey, plasma was obtained from 212 of them. Six
patients failed to participate due to: Temporary travel to
another area (n = 3), error in specimen preparation (n = 1)
or unknown (n = 2). The study profile is presented in fig-
ure 1.
Median follow-up time among 212 patients included in
this study was 22.3 months (interquartile range [IQR]
14.0–29.9). Median age was 35 years (IQR 29–43), and
158 patients (74.5%) were women. At the time of ART ini-
tiation, 110 (52.1%) had clinical AIDS (WHO stage 4).
The most common AIDS defining events were: Wasting
syndrome (87.3%), oesophageal candidiasis (10.9%),
Profile of the study cohort, Haydom Lutheran Hospital, Tan-zania, 2003–08Figure 1
Profile of the study cohort, Haydom Lutheran Hospi-
tal, Tanzania, 2003–08.
549 adults who started 
ART
271 adults on ART alive 
and in care
212 obtained viral load
187 with viral load 
<400 copies/ml
25 with viral load  
>400 copies/ml
126 died
79 transferred out
46 lost to follow-up
27 stopped treatment
50 on ART <6 months
3 on second-line ART
6 unable to obtain viral 
load 
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extrapulmonary tuberculosis (4.5%) and Kaposi's sar-
coma (4.5%). Initial ART regimen was stavudine/lamivu-
dine/nevirapine in 122 patients (57.5%), stavudine/
lamivudine/efavirenz in 39 (18.4%), zidovudine/lamivu-
dine/nevirapine in 45 (21.2%), and zidovudine/lamivu-
dine/efavirenz in 6 (2.8%). Among 66 patients with a
baseline CD4 measurement, median CD4 cell count was
118 cells/mL (IQR 51–189).
Virological results
Overall, 187 patients (88.2%; 95% CI 83.1–92.2) had
suppressed viraemia (<400 copies/mL). Two patients
(0.9%) had 400–1000 copies/mL, 14 (6.6%) had 1000–
10,000 copies/mL, 5 (2.4%) had 10,000–100,000 copies/
mL, and 4 (1.9%) had >100,000 copies/mL. The propor-
tion of patients (95% CI) with suppressed viraemia after
1, 2, 3 and 4 years was 94.8% (87.2–98.6), 88.0% (79.0–
94.1), 75.0% (57.8–87.9) and 87.5% (61.7–98.4), respec-
tively (figure 2). The small number of patients who
received ART for 3 and 4 years (n = 36 and n = 16, respec-
tively) gave rise to wide confidence intervals for those
groups.
Genotyping was successful in 22 of 23 samples with viral
load >1000 copies/mL. HIV-1 subtypes were A (n = 3), C
(n = 7), D (n = 8) and CRF01_AE (n = 2), whereas 2 were
inconclusive (different subtypes in the protease and
reverse transcriptase genes). Among those successfully
genotyped, 18 patients (82%) harboured at least one clin-
ically relevant resistance mutation in the reverse tran-
scriptase gene (table 1). The most frequent mutations
were M184I/V (n = 14; 64%), conferring resistance to lam-
ivudine, and K103N (n = 6; 27%), Y181C (n = 6; 27%)
and G190A (n = 6; 27%), conferring resistance to non-
nucleoside reverse transcriptase inhibitors (NNRTIs). Thy-
midine analogue mutations (TAMs), associated with
cross-resistance to all nucleoside reverse transcriptase
inhibitors (NRTIs), were found in 5 patients (23%), of
whom 1 had ³3 TAMs. Fourteen patients (64%) had dual-
class resistance, i.e. resistance to both NRTIs and NNRTIs.
None had clinically relevant mutations in the protease
gene.
Hence, in total, 18 of 212 patients (8.5%; 95% CI 5.1–
13.1) harboured drug resistance by use of a standard gen-
otyping assay. The prevalence (95% CI) of any clinically
significant drug resistance after 1, 2, 3 and 4 years was
3.9% (0.8–11.0), 8.4% (3.5–16.6), 16.7% (6.4–32.8) and
12.5% (1.6–38.3), respectively (figure 2). Dual-class
resistance was observed in 3.9% (0.8–11.0), 6.0% (2.0–
13.5), 13.9% (4.7–29.5) and 6.3% (0.2–30.2), respec-
tively. Again, the small number of patients on ART for 3
and 4 years gave rise to wide confidence intervals.
Predictors of drug resistance
In univariable logistic regression analysis only duration of
ART was significantly associated with emergence of drug
resistance (³3 years on ART; odds ratio [OR] 4.49; 95% CI
1.13–17.8; P = 0.033). Anemia (hemoglobin <10 g/dL;
OR 2.84; 95% CI 0.97–8.32; P = 0.058) and lymphopenia
(total lymphocyte count <1.2 × 109/L; OR 2.91; 95% CI
0.99–8.53; P = 0.052) were borderline significant. No
associations were found for age, sex, clinical stage, body
mass index or initial ART regimen. In multivariable anal-
ysis where duration of ART, anemia and lymphopenia
were included using the forward stepwise method, only
duration of ART remained in the final model, with the
same odds ratio and P-value as above (table 2).
Two patients with low-level viraemia (400–1000 copies/
mL) and one patient whose genotyping failed were
assumed not to harbour resistance in our study. To assess
whether this assumption might have biased our results,
we conducted a sensitivity analysis where these patients
were classified as resistant. In the resulting multivariable
model, both duration of ART (³3 years on ART; OR 6.47;
95% CI 1.28–32.6; P = 0.024) and lymphopenia (total
lymphocyte count <1.2 × 109/L; OR 4.24; 95% CI 1.48–
12.2; P = 0.007) were significantly associated with resist-
ance. Hence, the effect of lymphopenia might have been
Proportion of patients on ART with: A) suppressed viraemia (<400 copies/mL), and B) ³1 clinically significant resistance mutationFigure 2
Proportion of patients on ART with: A) suppressed 
viraemia (<400 copies/mL), and B) ³1 clinically signif-
icant resistance mutation. Vertical lines indicate 95% 
confidence interval.
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underestimated by misclassification bias in the main anal-
ysis, whereas duration of ART was a strong and significant
predictor of resistance in both analyses.
Discussion
Virological suppression rates were good up to 4 years after
starting ART in a rural Tanzanian hospital. These results
are in keeping with early reports from resource-limited
settings, where short-term virological efficacy rates were as
good as those reported from Europe and North America
[8]. We show that suppression of viraemia can be sus-
tained for several years even in rural Africa, where logisti-
cal support is challenging and patients often live in
poverty. However, like in many other African ART pro-
grams the attrition rate was high, and strategies to reduce
early mortality and other program losses need to be iden-
tified [11,12,22,23].
Experiences elsewhere have shown that poorly managed
HIV programs can give rise to widespread drug resistance
[24]. A number of factors may have contributed to the sus-
tained virological efficacy of the ART program in the
present study. First, all treatment and care for HIV-
infected patients was provided free of charge, which has
previously been shown to improve treatment efficacy [8].
Second, all patients had three days of adherence counsel-
ling with a nurse prior to starting ART. Third, a close col-
laboration between the clinical staff and a network of
community home-based carers ensured follow-up of
patients in their villages. Fourth, regular educational peer-
Table 1: Genotypic resistance results in 23 patients on ART with virological failure (HIV-1 RNA >1000 copies/mL)
ID Sex Age ART regimen: initial 
(currenta)
Months on ART Subtype Viral load Protease mutations Reverse transcriptase 
mutations
34 M 24 ZDV/3TC/NVP 
(ZDV/3TC/EFV)
42.1 C 434,131 M36I, L63P, H69K, I93L K103N
84 M 30 d4T/3TC/EFV 
(d4T/3TC/NVP)
49.1 D 8690 I13V, L33V, M36I, I64V K103N, M184V
224 M 32 d4T/3TC/NVP 34.7 C 1349 M36I, L63P, H69K, I93L
240 M 43 d4T/3TC/EFV 
(d4T/3TC/NVP)
35.5 CRF01_AE 81,691 I13V, M36I, L63P, H69K D67N, K70R, K103N, 
V179T, M184V, K219Q
275 F 41 d4T/3TC/NVP 32.3 D 477,518 I13V, K20R, M36V, L63P, 
I64V, I93L
G190A
282 F 32 d4T/3TC/NVP 32.4 A 2621 L10I, I13V, M36I, H69K M184V, Y188C
307 F 35 d4T/3TC/NVP 
(d4T/3TC/EFV)
31.7 Failed 2301 Failed Failed
321 F 34 d4T/3TC/NVP 30.4 D 1504 I13V, K20R, M36I, I62V, 
I64V
Y181C, M184I
366 F 48 d4T/3TC/NVP 28.3 C 3000 M36I, H69K, I93L K103N, V179T, M184V
401 F 44 d4T/3TC/NVP 28.6 C 2290 M36I, D60E, H69K, I93L G190A
402 F 40 d4T/3TC/NVP 
(d4T/3TC/EFV)
28.3 ?b 20,500 L10I, I13V, G16E, M36I, 
H69K
K101P, M184V, G190A, 
T215F
410 F 45 d4T/3TC/NVP 36.9 D 5990 I13V, L63P, I64V, V77I K101E, M184V, G190A
473 F 35 d4T/3TC/NVP 27.3 D 3965 I13V, I64V, V77I M41L, V75I, Y181C, M184V
476 F 19 ZDV/3TC/NVP 
(d4T/3TC/NVP)
26.5 D 1980 I64V G190A
516 F 24 d4T/3TC/EFV 24.0 C 419,979 M36I, L63P, H69K, I93L
554 F 28 ZDV/3TC/NVP 
(d4T/3TC/NVP)
24.0 C 1886 K20R, M36I, H69K
583 F 30 d4T/3TC/NVP 21.1 CRF01_AE 1432 L10V, G16E, M36IV, 
H69K
K103N, Y181C, M184V
611 F 33 d4T/3TC/NVP 17.8 C 15,600 M36I, I62V, L63P, H69K, 
V82I, I93L
K65R, V75I, V108I, Y181C, 
M184V, L210W
643 F 37 d4T/3TC/NVP 31.3 D 2400 K20R, M36I, I62V, I64M K70R, Y181C, M184V
749 F 32 d4T/3TC/EFV 
(d4T/3TC/NVP)
19.0 ?c 35,400 I13V, M36I, H69K K103N, M184V
752 F 35 d4T/3TC/NVP 14.5 A 3101 L10I, M36I, H69K Y181C, M184V
785 F 26 d4T/3TC/NVP 
(d4T/3TC/EFV)
14.6 D 3,683,117 I13V, M36I, D60E, I64V
982 F 15 d4T/3TC/NVP 8.5 A 76,700 I13V, M36I, L63P, H69K, 
V82I
V179T, M184V, G190A
aOnly specified if different from initial regimen.bCRF_01AE in the protease and A in the reverse transcriptase gene. cA in the protease and 
CRF_01AE in the reverse transcriptase gene.
ART, antiretroviral treatment; d4T, stavudine; 3TC, lamivudine; NVP, nevirapine; EFV, efavirenz; ZDV, zidovudine.
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support meetings contributed to reduce the stigma and
isolation many patients experience after receiving an HIV
diagnosis. Fifth, antiretroviral drug supply continuity was
uninterrupted from the beginning of the program. And
finally, visiting HIV physicians focused on capacity build-
ing of local clinical officers, with emphasis on common
curable opportunistic infections, such as tuberculosis,
candidiasis, cryptococcal meningitis and cerebral toxo-
plasmosis.
Overall, emergence of drug resistance was relatively
uncommon; only 8.5% harboured clinically significant
resistance mutations. Although the proportion of patients
with drug resistance was low, however, in a high-preva-
lence country like Tanzania the absolute number of indi-
viduals in need of second-line ART can rapidly become
substantial. If our results were extrapolated to Tanzania as
of December 2007 [1], then 11,500 patients would har-
bour drug resistance and be in need of second-line ART.
Such an extrapolation is not necessarily valid, but it illus-
trates the magnitude of the problem that drug resistance
can inflict on national ART programs. The number of indi-
viduals receiving ART has increased 20-fold over the past
4 years in sub-Saharan Africa [1], but access to second-line
antiretroviral drugs is still limited in many developing
countries due to higher costs and lack of fixed-dose com-
binations. Our study underscores the growing global need
for affordable and convenient second-line antiretroviral
regimens.
The prevalence of drug resistance increased with time and
reached approximately 15% after 3–4 years on ART. Most
previous studies on ART in Africa have focused on early
treatment efficacy, showing good virological results with a
limited observation time [10,12,25]. Only a few studies
have assessed long-term (>2 years) emergence of drug
resistance in sub-Saharan Africa. An early study from Sen-
egal showed that 12.5% had one or more drug resistance
mutations after a median of 30 months on ART [26],
whereas a recent study from Côte d'Ivoire found 22%
resistance after a median of 37 months on ART [27]. These
results should not be used as an argument against HIV
treatment in Africa; in fact, the results are comparable to a
recent study from Canada, where 20% developed resist-
ance after 30 months on the ART regimen most widely
used in resource-limited settings (stavudine/lamivudine/
nevirapine) [28]. Thus, emergence of drug resistance
appears to occur at a similar rate in Africa as in a Western
setting.
Of concern, among 18 patients with drug resistance muta-
tions, 14 harboured dual-class resistance. All 14 had a
combination of M184I/V, conferring resistance to lamivu-
dine, with one or more of K103N, Y181C and G190A,
conferring resistance to NNRTIs. Five of these patients
also had thymidine analogue mutations (TAMs), associ-
ated with cross-resistance to all NRTIs. In 3 patients the
standard second-line regimen in Tanzania would not be
adequate, i.e. would not introduce at least 2 fully active
drugs, which is the recommended strategy in treatment
failure [29]. Other studies from low- and middle-income
countries, using the same first-line treatment, have found
a similar pattern. In a recent study from Angola, 65% of
patients with virological failure had dual-class resistance
[30]. Furthermore, a study from Thailand found that sec-
ond-line treatment options, in the absence of newer
antiretroviral drugs, were limited for 48% of patients fail-
ing their initial regimen [31]. Expanding access to newer
antiretroviral drugs, including new HIV drug classes,
should be a priority in the global efforts to control HIV/
AIDS.
Table 2: Predictors of drug resistance in 212 HIV-infected adults on ART in rural Tanzania
Univariablea Multivariableb
Predictor variables OR (95% CI) P OR (95% CI) P
Duration of ART
1 year 1 1
2 years 2.27 (0.57–9.12) 0.247 2.27 (0.57–9.12) 0.247
³ 3 years 4.49 (1.13–17.8) 0.033 4.49 (1.13–17.8) 0.033
Hemoglobin
³ 10 g/dL 1
<10 g/dL 2.84 (0.97–8.32) 0.058 NS
Total lymphocyte count
³ 1.2 × 109/L 1
<1.2 × 109/L 2.91 (0.99–8.53) 0.052 NS
a No significant associations were found for age, sex, clinical stage, body mass index or initial ART regimen.
bStepwise multivariable logistic regression using a forward selection procedure. NS denotes that the variable did not meet the significance level 
criterion (P <0.05) for inclusion in the final model.
OR, odds ratio; CI, confidence interval; ART, antiretroviral therapy.
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It has been shown that in the presence of a failing ART reg-
imen, resistance mutations accumulate, jeopardizing
future treatment options [32]. Early detection of treat-
ment failure rely on viral load measurements, a standard
component of ART programs in resource-rich countries
[29]. In the present program, like in most resource-limited
settings, viral load was not measured routinely, and treat-
ment failure had to be assessed by clinical signs and CD4
cell counts. However, clinical signs and CD4 decline, as
recommended by WHO to detect treatment failure in the
absence of viral loads, have poor sensitivity and specifi-
city, and result in frequent misclassifications [33,34].
Hence, there is an urgent need for a simple, affordable
viral load assay adapted for use in basic, tropical environ-
ments, so that treatment failure can be detected before
multiple mutations occur.
In our study only duration of ART was significantly asso-
ciated with emergence of drug resistance. Baseline anemia
and lymphopenia were borderline significant in univaria-
ble analysis, and our sample size might have been too
small to reveal a true association. Other studies have
found that low CD4 cell count and high viral load at base-
line increase the risk of drug resistance [35]; however,
these measurements were not available in our study.
There were some weaknesses of this study. First, virologi-
cal efficacy could only be assessed in patients who were
alive and in care. A high early mortality accounted for
most of the program loss, which probably reflected
advanced immunodeficiency at enrolment rather than
treatment failure [17]. Many patients were transferred out
when the National AIDS Control Program started scaling
up ART in other villages, but it is unlikely that this intro-
duced any systematic bias. Among patients who stopped
treatment (4.9%) or were lost to follow-up (8.4%), there
was probably a proportion who either died or developed
drug resistance. Our study must be considered an "on-
treatment" analysis, and virological suppression rates and
resistance estimates in an "intention-to-treat" analysis
would have been poorer. Another limitation of this study
was the lack of longitudinal viral load and resistance
results. A cross-sectional virological survey may be more
influenced by random biological variations and labora-
tory artefacts, being derived from a single time point. Also,
we can not ascertain whether drug resistance mutations
existed prior to initiation of ART, which was recently
observed in rural South Africa [36], or developed during
treatment. However, Haydom Lutheran Hospital was the
first ART provider in the area, and single-dose nevirapine
was not used for PMTCT, so it is unlikely that there was
any significant primary resistance. Furthermore, this study
was limited by lack of adherence data, which is considered
the most important predictor of resistance [35]; however,
adherence estimates would not have altered our conclu-
sions. Finally, this was a hospital based study and proba-
bly there was a selection bias towards more advanced
immunodeficiency at baseline, which has previously been
shown to increase the risk of drug resistance [35]. On the
other hand, late presentation has been observed in many
African ART programs [10-12,25,37,38], and we believe
our findings can be representative of other similar set-
tings.
Conclusion
We found good virological suppression rates up to 4 years
after initiating ART in a rural hospital in Tanzania. These
results suggest that ART can be safely scaled up in rural
Africa with similar long-term virological efficacy rates as
those reported for industrialized countries. However,
prevalence of drug resistance increased with time, and
dual-class resistance was common, raising concerns about
exhaustion of future antiretroviral drug options. Earlier
detection of treatment failure and timely switch to sec-
ond-line ART could reduce accumulation of drug resist-
ance, underscoring the growing need for virological
monitoring in resource-limited settings. This study might
provide a useful forecast of drug resistance and demand
for second-line antiretroviral drugs in rural Africa in the
coming years.
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